<base href="http://www.pni.org">
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html><!-- InstanceBegin template="/Templates/submenus.dwt" codeOutsideHTMLIsLocked="false" -->
<head>
<!-- InstanceBeginEditable name="doctitle" -->
<TITLE>Controlled Analysis of Subjective <a href="/esp/medicine/brain/TL">Temporal Lobe & SPE | Pacific Neuropsychiatric Institute</a>Paranormal Experiences in Temporal Lobe Dysfunction in a Neuropsychiatric Population | Pacific Neuropsychiatric Institute</TITLE>
<!-- InstanceEndEditable --> 
<META NAME="description" CONTENT="The Pacific Neuropsychiatric Institute
(PNI) is involved with comprehensive evaluation and management in
Neuropsychiatry and Psychopharmacology at the clinical, research,
forensic, education and phenomenologic levels.">
<META NAME="keywords" CONTENT="Vernon Neppe, medicine, psychopharmacology,
neuropsychiatry, forensic psychiatry, neuropsychiatric, institute,
education, lectures, brain, forensics, journal, internet journal, Neppe,
neurotransmitters, medical ethics, questionnaire, research instruments,
caffeine, philosophy, vortex pluralism, epileptology, anomalous, informed
consent, pharmacology, neuropsychology, clinical medicine, mental health,
brain injury, epilepsy, seizure, head injury, deja vu, anomalistic
experience, parapsychology, phenomenology">

<LINK REL="stylesheet" TYPE="text/css" HREF="http://www.pni.org/styles.css">

<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">

<script language="JavaScript" type="text/JavaScript">
<!--
function MM_displayStatusMsg(msgStr) { //v1.0
  status=msgStr;
  document.MM_returnValue = true;
}
//-->
</script>
<!-- InstanceBeginEditable name="head" --><!-- InstanceEndEditable -->
</head>

<body text="#000000" link="#990000" vlink="#990000" alink="#990000" onLoad="MM_displayStatusMsg('PNI.org | Pacific Neuropsychiatric Institute');return document.MM_returnValue">
<a name="top"></a> 
<table width="700" border="1" align="center" cellpadding="0" cellspacing="0" bordercolor="#000000">
  <tr> 
    <td><table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="C4D2FF">
        <tr> 
          <td><a href="/"><img src="../../header.jpg" width="700" height="127" border="0"></a></td>
        </tr>
        <tr>
          <td>
		  <div align="right">
				<a href="http://brainvoyage.com/">www.brainvoyage.com</a>
				 | <a href="http://vernonneppe.org/">www.vernonneppe.org</a>
				 | <a href="http://vernonneppe.com/">www.vernonneppe.com</a>
				 | <a href="http://ecao.us/">www.ecao.us</a>&nbsp;
			</div>
			<div align="left" >
				<script>
				  (function() {
					var cx = '009175660163571863627:du9tocqgd6q';
					var gcse = document.createElement('script');
					gcse.type = 'text/javascript';
					gcse.async = true;
					gcse.src = 'https://cse.google.com/cse.js?cx=' + cx;
					var s = document.getElementsByTagName('script')[0];
					
					s.parentNode.insertBefore(gcse, s);
				  })();
				</script>
				<gcse:search></gcse:search>
			</div>
			<table width="100%" border="0" cellspacing="0" cellpadding="15">
              <tr>
                <td width="100%"><p><font size="3" face="Arial, Helvetica, sans-serif"><strong>
                    <a href="http://pni.org/neuropsychiatry/">NEUROPSYCHIATRY and BEHAVIORAL NEUROLOGY</a>
                     | 
                    <a href="http://pni.org/psychopharmacology/">PSYCHOPHARMACOLOGY</a><br><a href="http://pni.org/forensics/">FORENSICS</a> | <a href="/research/">RESEARCH</a>
					 | 
                    <a href="http://pni.org/consciousness/">CONSCIOUSNESS</a>
					 | 
                    <a href="http://pni.org/philosophy/">PHILOSOPHY</a> | <a href="http://www.brainvoyage.com/ctbm/">BOOKS</a> | <a href="/books/">LITERATURE</a><br>
                    <a href="http://pni.org/perspective.html">PERSPECTIVES</a>
                    | <a href="http://pni.org/clinical/">CLINICAL</a> | <a href="http://pni.org/research/anomalous/deja/">D&Eacute;J&Agrave; VU</a> | 
                    <a href="http://pni.org/interesting/">INTERESTING AREAS</a> | <a href="http://pni.org/philosophy/ethics/">ETHICS</a>
                    | <a href="http://pni.org/about_pni.html">CONTACT</a></strong></font></p>
                <p>
					<strong>
						KEY ARTICLES:
						<a href="http://www.pni.org/neuropsychiatry/consciousness/">CONSCIOUSNESS</a> | 
						<a href="http://pni.org/key-articles/double-blind.html">DOUBLE BLIND</a> | 
						<a href="http://pni.org/neuropsychiatry/chit/">HEAD INJURY</a> | 
						<a href="http://pni.org/neuropsychiatry/narcolepsy/">NARCOLEPSY</a> | 
						<a href="http://www.pni.org/neuropsychiatry/paroxysmal/">PAROXYSMAL DISORDERS</a> | 
						<a href="http://pni.org/psychopharmacology/principles/">PRESCRIPTION PRINCIPLES</a> | 
						<a href="http://www.pni.org/neuropsychiatry/tardive_dyskinesia/">TARDIVE DYSKINESIA</a> |
						<a href="http://www.pni.org/neuropsychiatry/moral_philosophy/">MORAL PHILOSOPHY</a>
						</strong>
						<p>
					<strong>
						Enduring Interest: </strong>
						<a href="http://www.pni.org/psychopharmacology/generics">Generic Substitution</a> | 
						<a href="http://www.pni.org/intelligence/">Genius</a> | 
						<a href="http://www.pni.org/groundbreaking/">Groundbreaking Paradigm Shifts</a> | 
						<a href="http://www.pni.org/ethics/security/">Zmail</a> |
						<a href="http://www.pni.org/philosophy/">Philosophy</a>
					
				</td>
              </tr>
            </table>
            <table width="100%" border="0" cellspacing="0" cellpadding="0">
              <tr> 
                <td class="bodyText" valign="top"><!-- InstanceBeginEditable name="content" -->
         

<div class=Section1>

<p class=MsoBodyTextIndent align=center style='text-align:center'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext;text-transform:
uppercase'>A Controlled Analysis of Subjective Paranormal Experiences in
Temporal Lobe Dysfunction in a Neuropsychiatric Population<o:p></o:p></span></p>

<p class=MsoBodyTextIndent align=center style='margin-top:0in;text-align:center'><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;color:windowtext;text-transform:uppercase'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-variant:small-caps !msorm;text-transform:none !msorm'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;text-transform:uppercase'><span
style='mso-prop-change:"David Turissini" 20051221T1940'>By John Palmer and
Vernon M. Neppe</span></span></span><a style='mso-footnote-id:ftn1'
href="#_ftn1" name="_ftnref1" title=""><span style='font-variant:small-caps !msorm;
text-transform:none !msorm'><span class=MsoFootnoteReference><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;text-transform:uppercase'><span
style='mso-prop-change:"David Turissini" 20051221T1940'><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";text-transform:uppercase;mso-ansi-language:
EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><span
style='mso-prop-change:"David Turissini" 20051221T1940'>[1]</span></span></span><![endif]></span></span></span></span></span></a><span
style='font-variant:small-caps !msorm;text-transform:none !msorm'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;text-transform:uppercase'><span
style='mso-prop-change:"David Turissini" 20051221T1940'><o:p></o:p></span></span></span></p>
<center>
<table width="90%" border="1" bordercolordark="#666666" bordercolorlight="#666666" cellspacing="0" cellpadding="5" noshade>
<tr>
<td >
Palmer J, Neppe, VM . A controlled analysis of subjective paranormal experiences in temporal lobe dysfunction in a neuropsychiatric population. Journal of Parapsychology, 2003, 67:1, 75-98.
<br><br>
Our thanks to the Journal of Parapsychology  for permission to republish this. 
<br><br>
The research was supported by an international Bial Grant funded from Portugal.
<br><br>
A companion article is : 
<br>
Palmer J, Neppe, VM, Exploratory Analyses of Refined Predictors of Subjective ESP 
Experiences and Temporal Lobe Dysfunction in a Neuropsychiatric Population. 
European Journal of Parapsychology, 2004, 19, 44-65.  we link here to the landing page. 
<br><br>
These two critically important papers extend the original research of Drs Neppe on subjective paranormal experience and the temporal lobe demonstrating anomalous temporal lobe functioning is both state and trait related to subjective paranormal experience.
<br><br>
Neppe VM. Temporal lobe symptomatology in subjective paranormal experients. Journal of the American Society for Psychical Research . 1983; 77 (1): 1-29  (not yet available on the Internet)
</td>
</tr>
</table>
</center>
<p class=MsoNormal style='margin-top:6.0pt'><b style='mso-bidi-font-weight:
normal'><center><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>------------------------------------------------------------------------------------------------------<o:p></o:p></span></center></b></p>

<h3 style='margin-top:0in'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>ABSTRACT:<span style='mso-spacerun:yes'>  </span>This research extended
to a neuropsychiatric population findings by Neppe and by Persinger that
subjective paranormal experiences (SPEs) are associated with temporal lobe
dysfunction (TLD) in the brain.<span style='mso-spacerun:yes'>  </span>The
sample consisted of 100 of Neppe's patients at the Pacific Neuropsychiatric
Institute in Seattle, WA.<span style='mso-spacerun:yes'>  </span>TLD was
defined as a composite of 4 diagnostic criteria: (a) symptomatology as measured
by 16 TLD-specific items from Neppe's INSET questionnaire; (b) predisposing
conditions (recreational drugs, brain damage); (c) anomalous
electroencephalographic (EEG) activity; and (d) response to anti-convulsant
drugs. SPEs were measured by questions on the INSET referring to ESP,
apparitional, and out-of-body experiences. TLD criteria and SPEs were coded
independently by 2 raters, each of whom were sent portions of patient files
from which information relevant to the other rater had been removed.<span
style='mso-spacerun:yes'>  </span>60 patients classified as having TLD had
significantly more SPEs than 27 patients who were not (p&lt;.05, one-tailed).<span
style='mso-spacerun:yes'>  </span>13 borderline patients on TLD were removed.
Supplementary regression analyses revealed that this result was due entirely to
symptoms (INSET) as predictor (<i style='mso-bidi-font-style:normal'>p</i> &lt;
.001).<span style='mso-spacerun:yes'>  </span>Females reported significantly
more TLD symptoms and SPEs than males, but this confound did not destroy the
INSET-SPE relationship.<span style='mso-spacerun:yes'>  </span>Phone interviews
of 20 patients reporting SPEs confirmed that the great majority had at least
one credible ESP experience.<span style='mso-spacerun:yes'>   </span><o:p></o:p></span></h3>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><center><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>--------------------------------------------------------------------------------------<o:p></o:p></span></center></b></p>

<p class=MsoNormal style='margin-top:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Our understanding of psi
from a physiological point of view would be greatly enhanced if we could
pinpoint a section of the brain in which psi mediation occurs, or at least an
area that plays a primary role.<span style='mso-spacerun:yes'>  </span>Such knowledge
would provide at least three concrete benefits. First, by considering the
functions performed by this part of brain, we could develop more incisive
insights about how psi manifests.<span style='mso-spacerun:yes'>  </span>For
instance, if the area plays a crucial role in the activation of memories,
credence would be lent to the hypothesis that psi occurs by activating stored
memories (Roll, 1966).<span style='mso-spacerun:yes'>  </span>Second, if
momentary brain states could be found to correlate with the accuracy of
discrete psi responses, progress could be made in predicting which particular
psi responses (e.g., guesses on a card test) will prove to be correct.<span
style='mso-spacerun:yes'>  </span>Third, attempts could be made through
biofeedback, drugs, or other means to alter the functioning of this part of the
brain to enhance psi performance.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>The earliest example of an
exploration of the relation between SPEs and the temporal lobes is an
uncontrolled study by Nelson (1970), who found that 10 of 12 trance mediums had
evidence of temporal lobe instability in their EEGs. Subsequently, Nelson and
Neppe (1980) did not replicate these EEG findings in the population from the
South African Society for Psychical Research (SASPR) studied by Neppe (see
below).<span style='mso-spacerun:yes'>  </span>Roll (1977) suggested a link
between epilepsy and poltergeist activity, based on the fact that 22 of 92
persons regarded as the foci of such activity that he surveyed were prone to
"seizures or dissociative states" (p. 400).<span style='mso-spacerun:yes'> 
</span>In one particularly noteworthy case (Solfvin &amp; Roll, 1976),
poltergeist outbursts appeared to alternate with seizures in a grand mal
epileptic.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>The first controlled study
to investigate the relationship between temporal lobe instability and SPEs was
by Neppe (1979, 1980b, 1981a, 1982, 1983b), who analyzed the SPEs reported by
all members of the SASPR.<span style='mso-spacerun:yes'>  </span>He found that
a core group of six members reported large numbers of SPEs according to
pre-stipulated criteria.<span style='mso-spacerun:yes'>  </span>These persons
had significantly more possible temporal lobe symptoms than a group of six
control subjects from the same society who reported no SPEs.<span
style='mso-spacerun:yes'>  </span>Data were collected from interviews and
detailed questionnaires.<span style='mso-spacerun:yes'>  </span>The latter
included the Neppe Temporal Lobe Questionnaire and several SPE questionnaires,
derived in part from a questionnaire developed by Palmer (1979).<span
style='mso-spacerun:yes'>  </span>These instruments were administered to
subjects verbally.<span style='mso-spacerun:yes'>  </span>The findings
demonstrated a link of temporal lobe functioning to SPEs at both a state and a
trait level, and also suggested a link of seizure type phenomena with these
experiences.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent2><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>Neppe later delineated a particular type of olfactory hallucination
associated with SPEs that is pleasant and perfumy but commonly co-exists with
temporal lobe type hallucinations (Neppe, 1983c, d).<span
style='mso-spacerun:yes'>  </span>This again supported the trait link of
temporal lobe firing with SPEs.<span style='mso-spacerun:yes'>  </span>Finally,
he demonstrated that the temporal lobe epileptic, the subjective paranormal
experient, the psychotic, and the normal subject each describe a specific
subtype of déjà vu experience (Neppe, 1981a, 1983a). <o:p></o:p></span></p>

<p class=MsoBodyTextIndent2><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>Persinger has published extensive research and theorizing on the role
of the temporal lobes in psi experiences. He attributes SPEs to instability or
micro-seizures in the temporal lobes, particularly the hippocampus and amygdala
(Persinger, 1989).<span style='mso-spacerun:yes'>  </span>He tested this
hypothesis by giving a 29-item scale of temporal lobe symptoms<span
style='mso-spacerun:yes'>  </span>and a scale measuring seven different types
of SPEs (including telepathy, out-of-body, and spiritual experiences) to groups
of 108 and 41 college students (Persinger, 1984).<span
style='mso-spacerun:yes'>  </span>These scales were a direct derivation of
Neppe's original Temporal Lobe and SPE questionnaires. (Neppe, 1981a, b,
c)<span style='mso-spacerun:yes'>  </span>In both samples there were
significant positive correlations between scores on the temporal lobe scale and
number of different kinds of SPEs reported. This research was replicated and
extended with a sample of 99 college students, who were given a 16-item scale
measuring complex partial epileptic signs (CPES) in addition to the scale used
previously (Persinger &amp; Vaillant, 1985).<span style='mso-spacerun:yes'> 
</span>Both scales yielded significant positive correlations with the number of
different kinds of SPEs.<span style='mso-spacerun:yes'>   </span>It is also
noteworthy that persons engaged in artistic professions score high on
Persinger's temporal lobe scales (Persinger &amp; Makarec, 1993) and also show
exceptionally positive results in ESP Ganzfeld experiments (Palmer &amp;
Broughton, 2000). <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Persinger's TL scales have
been validated in two ways.<span style='mso-spacerun:yes'>  </span>First, it was
shown that epileptics score substantially higher than controls on the scales
(Persinger &amp; Makarec, 1993). Second, amount of EEG alpha activity in the
temporal lobe, but not the occipital lobe, was greater among high than low
scorers on Persinger's scales (Makarec and Persinger, 1990).<span
style='mso-spacerun:yes'>  </span>However, the scales do not show particularly
good discriminant validity as measures of temporal-lobe epilepsy.<span
style='mso-spacerun:yes'>  </span>Clinical groups suffering from post-traumatic
stress disorder, anxiety-depersonalization, and "exotic dissociation" scored
quite high on the scales (although not as high as the epileptics), and the
scales correlate extremely highly (.72 to .83) with the Bernstein-Putnam
Dissociative Experiences Scale (Persinger &amp; Makarec, 1993). <o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='text-indent:.5in'><span style='font-size:
12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'><span
style='mso-spacerun:yes'> </span>All the above data involving the relationship
between temporal lobe symptoms and SPEs were collected from normal
populations.<span style='mso-spacerun:yes'>  </span>If the relationship between
these variables is truly linear, one would expect temporal lobe epileptics to
have even greater amounts of SPEs than normals who happen to score high on the
kinds of scales discussed above.<span style='mso-spacerun:yes'> 
</span>However, this remains to be established.<span style='mso-spacerun:yes'> 
</span>Persinger (1989) argues that repeated epileptic motor seizures destroy
brain tissue and thus might actually reduce the incidence of SPEs.<span
style='mso-spacerun:yes'>  </span>Sensky et al (1984)<span
style='mso-spacerun:yes'>  </span>found no tendency for diagnosed temporal lobe
epileptics to have more mystical experiences than control groups of primary
generalized epileptics and patients suffering from migraine.<span
style='mso-spacerun:yes'>  </span>However, the samples in each were group were
small in this study (<i style='mso-bidi-font-style:normal'>N</i> &lt; 30) and
the measurement of SPEs did not appear to be very thorough. Also, Hurst and
Neppe (1981) have described a familial link between seizures and SPEs and as a
consequence developed the term "psi-genetics" (Neppe &amp; Hurst, 1982).<span
style='mso-spacerun:yes'>  </span>Clearly, more research is needed to settle
the issue.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent2><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>An opportunity to derive more information from clinical populations is
provided by Neppe, who sees many temporal lobe epileptics in his clinical
practice at the Pacific Neuropsychiatric Institute in Seattle.<span
style='mso-spacerun:yes'>  </span>He collects enormous amounts of data from
each individual, including etiology, current symptoms, EEG data, and responses
to anti-convulsant (A-C) drugs.<span style='mso-spacerun:yes'>  </span>His
symptom questionnaire<span style='mso-spacerun:yes'>  </span>includes questions
on SPEs.<span style='mso-spacerun:yes'>  </span>This<span
style='mso-spacerun:yes'>  </span>Short<span style='mso-spacerun:yes'> 
</span>Inventory of Neppe of Symptoms of Epilepsy and the Temporal Lobe (INSET)
serves as the basis for detailed analysis of every positive reported symptom of
temporal lobe disease, based on criteria developed initially by Neppe (1979,
1981 a, b, c) and later<span style='mso-spacerun:yes'>  </span>by Neppe and
Tucker (1988, 1992).<o:p></o:p></span></p>

<h2 align=left style='margin-top:6.0pt;text-align:left;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Although it is Neppe's
subjective impression that his TLD patients have an unusual number of SPEs and
more than his other patients, time constraints have prevented him from
analyzing these data quantitatively.<span style='mso-spacerun:yes'>  </span>The
purpose of the proposed project is to remedy this deficiency through a
collaborative effort involving other qualified individuals who have the time
and expertise to complete the task.<o:p></o:p></span></h2>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<h4 style='margin-top:6.0pt'><span style='font-variant:small-caps !msorm;
text-transform:none !msorm'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;text-transform:uppercase'><span style='mso-prop-change:"David Turissini" 20051221T1940'>Method<o:p></o:p></span></span></span></h4>

<h2><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></h2>

<h1 style='margin-bottom:6.0pt'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>Selection of Patients<o:p></o:p></span></h1>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:0in;text-indent:.5in'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>The initial plan was to evaluate 80
patients and to do a preliminary analysis of the hypothesis after the first
40.<span style='mso-spacerun:yes'>  </span>However, it soon became apparent
that a larger proportion of patients were falling into the TLD group than was
anticipated, raising the concern that the control group would be too small to
properly analyze.<span style='mso-spacerun:yes'>  </span>It was thus decided to
raise the total sample size to 100 patients and forgo the preliminary
analysis.<span style='mso-spacerun:yes'>  </span>Palmer (JP) and<span
style='mso-spacerun:yes'>  </span>Neppe (VN), who at the time were blind to the
patients' SPE scores, made this decision.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:0in;text-indent:.5in'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>Neuropsychiatric patients (with
neurological as well as psychiatric symptoms) were selected from among those
seen within the previous 6 months.<span style='mso-spacerun:yes'>  </span>In
most cases, follow-up sessions with such patients were anticipated. The folders
of these current patients were already arranged alphabetically by last name in
the files.<span style='mso-spacerun:yes'>  </span>Patients were entered into
the sample sequentially. An initial batch of 75 patient files passing the
original cut was selected by VN.<span style='mso-spacerun:yes'> 
</span>Additional batches totaling 36 files were later supplied to the raters.<span
style='mso-spacerun:yes'>  </span>The latter batches consisted of cases VN had
just completed reports on and were selected in the order of the report
completion.<span style='mso-spacerun:yes'>  </span>Thus, they were more recent
than the first batch.<span style='mso-spacerun:yes'>   </span>The total number
of patients exceeded 100 because 11 cases were later found to be invalid and
had to be replaced.<span style='mso-spacerun:yes'>  </span>8 of these were found
to have met the exclusion criteria, and 3 were found to be duplicates of
first-batch patients that mistakenly crept into the subsequent batches.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:0in;text-indent:.5in'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>All patients included in the sample
gave informed consent to have their files used for the research. Only 6 qualifying
subjects were excluded prior to processing because of absence of informed
consent. Prior to inclusion in the original sample, VN also excluded cases that
he knew met the following exclusion criteria: (a) under age 18 as of 1/1/2000,
(b) electroconvulsive therapy within the past 6 months, (c) a major
psychological disorder (mental retardation, active psychosis, dementia or
malingering), and (d) insufficient investigation despite full reports: this
usually involved absence of EEG data during the evaluation or in the preceding
six months.<span style='mso-spacerun:yes'>  </span>Approximately 15 to 20 cases
were excluded by these criteria. <o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt;margin-right:0in;
margin-bottom:6.0pt;margin-left:0in'><i style='mso-bidi-font-style:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Preparation
of Computer Files</span></i><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;color:windowtext'><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:0in;text-indent:.5in'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>At the outset, to preserve
anonymity, the names of patients were converted to their initials plus a digit.<a
style='mso-footnote-id:ftn2' href="#_ftn2" name="_ftnref2" title=""><span
class=MsoFootnoteReference><span style='mso-special-character:footnote'><![if !supportFootnotes]><span
class=MsoFootnoteReference><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>[2]</span></span><![endif]></span></span></a><span
style='mso-spacerun:yes'>  </span>VN's Microsoft Word computer files of his
patients are extensive, ranging in size from about 40 to about 120 typed
pages.<span style='mso-spacerun:yes'>  </span>Only some of the information in
the files was relevant to the coding criteria.<span style='mso-spacerun:yes'> 
</span>It was decided to have JP code the files for neurological problems and
Nebel (HN) for SPEs and to keep each rater blind to the material coded by the
other.<span style='mso-spacerun:yes'>  </span>To facilitate this blindness, the
files were edited to remove references to SPEs from the files sent to JP by
using the "find" command in Microsoft Word.<span style='mso-spacerun:yes'> 
</span>Likewise, information about TL and seizure symptoms was removed from the
files sent to HN.<a style='mso-footnote-id:ftn3' href="#_ftn3" name="_ftnref3"
title=""><span class=MsoFootnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'>[3]</span></span><![endif]></span></span></a><span
style='mso-spacerun:yes'>  </span>All this editing, including the removal of
patient names, was done by HN for the 82 patients and by Magill (SM) for the
last 18 patients.<a style='mso-footnote-id:ftn4' href="#_ftn4" name="_ftnref4"
title=""><span class=MsoFootnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'>[4]</span></span><![endif]></span></span></a><span
style='mso-spacerun:yes'>  </span>These files were then checked by VN to ensure
that the editing was done properly.<span style='mso-spacerun:yes'>  </span><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:0in;text-indent:.5in'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>It was admittedly less than ideal
for HN to edit the initial 82 files for neurological information, as this was
the information she was supposed to be blind to. Unfortunately, staff time and
number of staff assigned to the project required this arrangement. To<span
style='mso-spacerun:yes'>  </span>mitigate the problem, HN edited<span
style='mso-spacerun:yes'>  </span>by removing whole sections located by the
Word "find" command without reading them, deliberately did not read the folder
at all thereafter, and edited the whole set such that her own seeking of SPEs
was done at a<span style='mso-spacerun:yes'>  </span>time weeks or usually
months later when she regarded herself as blind.<span
style='mso-spacerun:yes'>  </span>In general, both raters (HN and JP) were
instructed to look only at the particular sections of the files containing the
information relevant to their respective rating tasks.<span
style='mso-spacerun:yes'>  </span><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Diagnostic
Information<o:p></o:p></span></i></p>

<p class=MsoBodyTextIndent style='margin-bottom:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>There were
4 specific classes of diagnostic information that the raters used to assess
whether patients were to be assigned to the TL group or to the control group.
They will be described briefly below.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt;margin-right:0in;
margin-bottom:6.0pt;margin-left:0in;text-indent:.5in'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Short
INSET</span></i><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;
color:windowtext'>.<span style='mso-spacerun:yes'>  </span>The Short form of
the Inventory of Neppe of Symptoms of Epilepsy and the Temporal Lobe (INSET) is
designed primarily to assess behavioral and subjective symptoms characteristic
of TLD and seizures.<span style='mso-spacerun:yes'>  </span>The part of the
INSET relevant for present purposes is a series of 53 multiple-choice
questions, each representing a symptom or class of symptoms characteristic of
neurological disorders of various kinds.<span style='mso-spacerun:yes'> 
</span>Each question has 7 response choices representing frequency of
occurrence. They are: (0) "never"; (1) "less than once per year"; (2) "yearly
or more"; (3) "monthly or more"; (4) "weekly or more"; (5) "daily"; and (6)
"more than daily". In some of the results found in the computer files, a
different set of response alternatives is sometimes reported that translates to
the preceding set according to the following transformations: (1-2) "rare"; (3)
"occasional"; (4-5) "frequent", and (6) "very frequent".<span
style='mso-spacerun:yes'>  </span>All questions are asked both for "recent
experience" and for "past experience".<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:0in;text-indent:.5in'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>Of the 53 questions, only 16 refer
to symptoms specifically characteristic of TLD.<span style='mso-spacerun:yes'> 
</span>These questions, listed in the Appendix, were the only ones used for TLD
classification.<span style='mso-spacerun:yes'>  </span>In addition, at the end
of the INSET are 4 questions referring to SPEs that were coded for this
project. Specifically, they address ESP experiences, out-of-body experiences
(OBEs), and apparitions.<span style='mso-spacerun:yes'>  </span>These
questions, which provided the SPE scores, are listed at the bottom of the
Appendix.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:0in;text-indent:.5in'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>Patients completed the INSET during
their first or second visit to PNI.<span style='mso-spacerun:yes'> 
</span>After completing it, VN interviewed them about their responses to each
question they answered affirmatively or were unclear about, to elicit further
information and to be sure the question was understood as intended.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:0in;text-indent:.5in'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>Neither the short INSET nor the
16-item subscale used for this research has undergone psychometric evaluation.
One purpose of this research is to provide such data, particularly the internal
reliability of the 16-item subscale (hereafter referred to simply as the
INSET).<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt;margin-right:0in;
margin-bottom:6.0pt;margin-left:0in;text-indent:.5in'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Etiology.
</span></i><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'><span
style='mso-spacerun:yes'> </span>During the initial interview, summarized in
the file under a section labeled "History of Main Complaint", and as part of
the INSET, patients were asked if they ever had a head injury or a brain
disease such as encephalitis or meningitis, brain surgery, or brain tumor.<span
style='mso-spacerun:yes'>  </span>They were also asked about the past and
current frequency of recreational drug use.<span style='mso-spacerun:yes'> 
</span>The specific drugs inquired about are marijuana, LSD, mescaline,
amphetamines, cocaine, phencyclidine (PCP), heroin, narcotics, alcohol,
caffeine, tobacco, and the ever-present "other". These results are summarized
in a table in the files labeled "Abuse History" and summarized briefly in the
report of the INSET.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt;margin-right:0in;
margin-bottom:6.0pt;margin-left:0in;text-indent:.5in'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>EEG</span></i><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>.<span
style='mso-spacerun:yes'>  </span>Patients at PNI are very commonly evaluated
electro-encephalographically. Depending on clinical indications, they receive
either or both of: <o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:.75in;text-indent:-.25in;mso-list:l1 level1 lfo1;mso-list-change:
"%1\:1\:4\:\." "Rhine Research Center" 20020927T1700;tab-stops:list .75in'><![if !supportLists]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'><span
style='mso-list:Ignore'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;color:windowtext'>18 channel wake and sleep EEGs including activation
procedures of hyperventilation and photic stimulation .<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-left:.7in;text-indent:-.2in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
mso-bidi-font-family:"Courier New"'>b.<span style='mso-spacerun:yes'>  
</span>2 to 3 days of 16 to 18 channel computerized home ambulatory EEG
monitoring with an ongoing record of the patient's brain waves during waking
activities as well as sleep.<span style='mso-spacerun:yes'>  </span>The
technology used is possibly the most sophisticated home EEG monitoring system
in the world, namely the Sleep-Wake DigiTrace apparatus. To accentuate the
clarity of records, and diminish outside artifact, playbacks used high digital
frequency filters. At times, when necessary, recordings were slowed to
facilitate more adequate reading and interpretation. Automated seizure computer
files, push-button events, and background EEG monitoring were used and stored
on computer.<span style='mso-spacerun:yes'>  </span>All tracings were
independently read by an acknowledged world expert on the DigiTrace technology
at Harvard University in Boston. Patients or families would press a pushbutton
when they thought a seizure, spell, event or other anomalous sensation may have
been happening or coming on, and these records were therefore marked and
correlated with the simultaneous brain-wave activity. Because of the referral
pool, VN uses placements to accentuate the temporal lobes most, so as to
extract a higher yield. In this research, almost invariably, a coronal temporal
montage was used, usually with added T1 and T2 electrode placements.<span
style='mso-spacerun:yes'>  </span>Additionally, these patients had
electrocardiographic monitoring to ensure that brain abnormalities were not
occurring concurrently with heart arhythmias.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-bottom:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>All but 7
of the100 patients in our sample were given the ambulatory EEG.<span
style='mso-spacerun:yes'>  </span>In 6 of these cases the exclusion was because
the sleeping and waking EEGs were both normal and their were no other reasons
to think the ambulatory EEG might yield a different verdict.<span
style='mso-spacerun:yes'>  </span>In one case, the patient resisted the
ambulatory EEG.<span style='mso-spacerun:yes'>  </span>The EEG results are
given in a section of the file specifically devoted to them and summarized in a
sub-section under the heading "Diagnosis". <o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:0in;text-indent:.5in'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'><span
style='mso-spacerun:yes'> </span>In a few cases, waking and sleep EEGs were not
conducted at PNI because they had recently been done elsewhere or it was felt
that going directly to ambulatory EEG was appropriate.<span
style='mso-spacerun:yes'>  </span>In these cases, the reports of these earlier
EEGs were considered for the coding.<span style='mso-spacerun:yes'>  </span><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt;text-indent:.5in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;color:windowtext'>Response to Anticonvulsant Medications</span></i><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>.<span
style='mso-spacerun:yes'>  </span>If the previously obtained diagnostic
information indicates that the patient is experiencing seizures and or is
likely to have TLD, they are generally given one of a variety of anti-convulsant
medications.<span style='mso-spacerun:yes'>  </span>Whether such a medication
is to be prescribed and the specific medication(s) of choice are listed in the
files under a section called "Specific Recommendations".<span
style='mso-spacerun:yes'>  </span>Response to these medications is documented
in the reports of follow-up visits the patients make to PNI.<span
style='mso-spacerun:yes'>  </span>The number of such visits reported in the
files varies greatly from patient to patient, depending in large part on the
recency of the initial visit. It is common for the dosage level of the A-C
medications to be varied over time, and sometimes patients are changed from one
A-C to another.<span style='mso-spacerun:yes'>  </span>These changes are
usually dictated by the effectiveness of the current regimen in ameliorating
the symptoms and also the presence of side effects.<span
style='mso-spacerun:yes'>  </span>It is common for patients to be prescribed
other drugs, such as anti-depressants or anti-anxiety agents, in addition to
the A-Cs.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Diagnostic
Coding<o:p></o:p></span></i></p>

<p class=MsoBodyTextIndent style='margin-bottom:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>At the
outset of the project, VN and JP agreed on a preliminary set of coding criteria
that were followed for the first patients evaluated.<span
style='mso-spacerun:yes'>  </span>However, it eventually became apparent that
some of these initial criteria were producing weird and unrealistic
distributions of scores.<span style='mso-spacerun:yes'>  </span>For instance,
the initial scoring scheme for TLD symptoms on the INSET produced an overwhelming
proportion of patients given the highest score (3). It was thus decided to
modify the criterion for scoring these INSET questions, most notably by
downgrading symptoms that appeared infrequently.<span
style='mso-spacerun:yes'>  </span>All such decisions were made by VN and JP
based primarily on characteristics of the overall distributions of scores, not
scores of individual patients, and, most importantly, without knowledge of SPE
scores.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt;margin-right:0in;
margin-bottom:6.0pt;margin-left:0in;text-indent:.5in'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>TLD
Symptoms (0 to 3)</span></i><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;color:windowtext'>.<span style='mso-spacerun:yes'>  </span>The frequency
scores on the 16 INSET items devoted to TLD were transformed as follows:<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>0<span
style='mso-spacerun:yes'>  </span>=<span style='mso-spacerun:yes'>     
</span>0 (never)<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>0.25 = <span
style='mso-spacerun:yes'> </span>1-2 (rare, yearly or less,<span
style='mso-spacerun:yes'>  </span>etc.)<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>0.50 =<span
style='mso-spacerun:yes'>  </span>3 (occasional, more than yearly up to
monthly, etc.)<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>1<span style='mso-spacerun:yes'> 
</span>=<span style='mso-spacerun:yes'>      </span>4-6 (frequent, more than
monthly, etc.)<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-bottom:6.0pt'><span style='font-size:
12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Each item was scored only
once; when the scores for "recent" and "past" differed, the highest was chosen.
The item scores were then summed to yield a total raw score, with a possible
range of 0 to 16, based on the scoring scheme above. The raw scores were then
transformed to the final classification scores as follows:<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>0 = 0 to 0.75<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>1 = 1 to 3.75<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>2 = 4 to 5.75<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>3 = 6 or higher<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt;margin-right:0in;
margin-bottom:6.0pt;margin-left:0in;text-indent:.5in'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Etiology
(0 to 2)</span></i><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;
color:windowtext'>.<span style='mso-spacerun:yes'>  </span>1 point was scored
if the patient had suffered a head injury, brain tumor, or brain disease (e.g.,
encephalitis).<span style='mso-spacerun:yes'>  </span>Head injuries only
counted if the patient experienced loss of consciousness, concussion, and/or
amnesia.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:0in;text-indent:.5in'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>1 point was scored if the patient
had a history of using certain recreational drugs.<span
style='mso-spacerun:yes'>  </span>If the frequency of use of any of the
following drugs met the defined standard, the point was scored:<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><i style='mso-bidi-font-style:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Marijuana</span></i><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>: Over many
years or very frequently over shorter periods of time<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><i style='mso-bidi-font-style:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Hallucinogens</span></i><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'> (LSD +
mescaline + PCP):<span style='mso-spacerun:yes'>  </span>3 or more times<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><i style='mso-bidi-font-style:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Amphetamines</span></i><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>: 6 months
or more, or at least 30 times (unless prescribed)<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
12.0pt;margin-left:.5in'><i style='mso-bidi-font-style:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Opiates</span></i><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>: 6 months
or more (unless prescribed and patient not an addict)<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:0in;text-indent:.5in'><i style='mso-bidi-font-style:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>EEG (0 to
3)</span></i><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;
color:windowtext'>.<span style='mso-spacerun:yes'>  </span>The EEG reports
generally contained information about the number of spikes and paroxysms in the
EEG records, their laterality and focality.<span style='mso-spacerun:yes'> 
</span>In most cases, the file also contained evaluative statements of the EEG
record regarding its indication of TLD.<span style='mso-spacerun:yes'> 
</span>In these cases, the following formula was used to arrive at a
classification score for EEG:<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>0 = "normal", "do not support" TLD<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>1 = "mildly abnormal", "weakly
support" TLD<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>2 = "abnormal", "support" or
"moderately support" TLD<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>3 = "severely abnormal", "strongly
support" TLD<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='text-indent:.5in'><span style='font-size:
12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>There were 16 files that did
not include evaluative EEG statements.<span style='mso-spacerun:yes'> 
</span>JP had guidelines giving some indication of what specific kinds of
abnormalities deserved what scores, but he found this difficult to apply to
specific cases.<span style='mso-spacerun:yes'>  </span>So he decided to extract
excerpts of the EEG abnormalities recorded in each file, eliminated any phrases
that might identify the patient (e.g., name of physician who had conducted
previous EEG examination), removed the patient initials that identified the
file, randomized the order of the cases, and emailed them to VN.<span
style='mso-spacerun:yes'>  </span>VN then supplied scores for the 16 cases. He
reported that he was unable to identify any of the patients from the material
sent.<a style='mso-footnote-id:ftn5' href="#_ftn5" name="_ftnref5" title=""><span
class=MsoFootnoteReference><span style='mso-special-character:footnote'><![if !supportFootnotes]><span
class=MsoFootnoteReference><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>[5]</span></span><![endif]></span></span></a><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt;text-indent:.5in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;color:windowtext'>A-C Response (-3 to 3)</span></i><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>.<span
style='mso-spacerun:yes'>  </span>The response of patients' symptoms to A-C
medications was coded on a 7-point scale from "much worse" (-3) to "much
better" (3).<span style='mso-spacerun:yes'>  </span>Where applicable, separate
judgments were made for seizures and psychological symptoms, and the most
positive result was chosen for coding.<span style='mso-spacerun:yes'> 
</span>When there were different results for different psychological symptoms,
the average was taken.<span style='mso-spacerun:yes'>  </span>Side effects,
insofar as they could be clearly identified as such, were ignored for purposes
of coding.<span style='mso-spacerun:yes'>  </span>Primary consideration was
given to the most recent evaluations and evaluations explicitly linked to an
A-C drug.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='text-indent:.5in'><span style='font-size:
12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Patients for whom no A-C
drug was recommended nor given by VN were coded 0.<span
style='mso-spacerun:yes'>  </span>Cases in which an A-C drug was recommended
but not given (e.g., because of a fear of untoward effects like side-effects or
patient resistance) were coded 1.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in'><i style='mso-bidi-font-style:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>TLD
Classification</span></i><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;
color:windowtext'><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:0in;text-indent:.5in'><i style='mso-bidi-font-style:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Objective
Classifications</span></i><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;color:windowtext'>.<span style='mso-spacerun:yes'>  </span>The
classification scores were summed over the 4 diagnostic categories (symptoms,
etiology, EEG, A-C response) to yield a TLD score with a possible range of -3
to 11. These were converted to classifications as follows:<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'><span
style='mso-spacerun:yes'> </span>6 to 11:<span style='mso-spacerun:yes'> 
</span>TLD Group<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>-3 to 4:<span
style='mso-spacerun:yes'>   </span>Control Group<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'><span
style='mso-spacerun:yes'> </span>5:<span style='mso-spacerun:yes'>          
</span>Indeterminate<o:p></o:p></span></p>

<p class=MsoBodyTextIndent><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;color:windowtext'>The indeterminate group was decided upon as a buffer
to help protect against misclassification. Patients in this group were
eliminated from the comparison testing the main hypothesis.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt;text-indent:.5in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;color:windowtext'>Clinical Classifications</span></i><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>.<span
style='mso-spacerun:yes'>  </span>As the name implies, the purpose of the above
coding scheme was to give an objective, quantified basis for patient
diagnoses.<span style='mso-spacerun:yes'>  </span>Blanket diagnostic statements
included in the files were not considered in these codings.<span
style='mso-spacerun:yes'>  </span>(Such statements were of limited use anyway,
because they predated and thus did not include A-C response).<span
style='mso-spacerun:yes'>  </span>Of course, VN made blanket diagnoses, either
explicitly or implicitly, during the course of treatment.<span
style='mso-spacerun:yes'>  </span>It is quite possible, if not likely, that
classification by the 2 methods could be different for a minority of difficult
to classify patients.<span style='mso-spacerun:yes'>  </span>Thus, it was
decided, as a secondary measure, to have VN classify each of the 100 patients
as TLD, control, or indeterminate -- mirroring the objective classifications.
For this purpose, JP sent VN a final list of the 100 patient file names
(initials) along with date of birth and gender.<span style='mso-spacerun:yes'> 
</span>These clinical evaluations were based on VN's recollections, which were
clearer for some patients than others.<span style='mso-spacerun:yes'> 
</span>He specifically did not consult the EEG, INSET, SPE, anticonvulsant
responsiveness or etiology data, but did review his overall diagnostic
assessment. <a style='mso-footnote-id:ftn6' href="#_ftn6" name="_ftnref6"
title=""><span class=MsoFootnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'>[6]</span></span><![endif]></span></span></a><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt;text-indent:.5in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;color:windowtext'>Final Classifications</span></i><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>.<span
style='mso-spacerun:yes'>  </span>After VN completed his clinical
classifications, JP sent his codes to VN.<span style='mso-spacerun:yes'> 
</span>VN examined these, noting discrepancies with his clinical
classifications.<span style='mso-spacerun:yes'>  </span>When there were
disagreements, he consulted the files and in most cases agreed with JP.<span
style='mso-spacerun:yes'>  </span>However, there were 8 instances where he
questioned the validity of JPs codings: 2 on EEG and 6 on A-C response.<span
style='mso-spacerun:yes'>  </span>He sent JP relevant excerpts from these files
and JP coded these excerpts blind.<span style='mso-spacerun:yes'>  </span>Then
VN sent JP the file IDs and JP went back to reassess the basis for his
codings.<span style='mso-spacerun:yes'>  </span>He did not automatically agree
with his coding of the excerpts, because his original codings had been
influenced by statements in the files other than those selected by VN.<span
style='mso-spacerun:yes'>  </span>He decided to change his codings on 5 of the
6 A-C responses, but not on the other A-C response and on 1 of the EEGs.<span
style='mso-spacerun:yes'>  </span>In the 5 A-C response cases, he found that he
had simply missed statements in the files that, had he been aware of them,
would have affected his original codings.<span style='mso-spacerun:yes'> 
</span>For the remaining EEG case, VN discovered that there was an error in the
file: the word "not" was erroneously introduced into a statement that should
have read "support" TLD. (This is credible, because a companion statement
immediately below the one in question said that the EEG results support
prescription of anti-convulsant drugs.)<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='text-indent:.5in'><span style='font-size:
12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'><span
style='mso-spacerun:yes'> </span>The net result was a reclassification of 5
patients from JP's original codes: 2 went from control to TLD, 1 went from TLD
to control, 1 went from indeterminate to control, and 1 went from control to
indeterminate. At this point, JP and VN agreed on the classification of 97 of
the 100 patients. 2 remaining patients, who were not among the 7 questioned by
VN earlier, had both been coded as control by JP; 1 was coded indeterminate and
the other TLD by VN.<span style='mso-spacerun:yes'>  </span>The third (who had
been shifted to the control group by JP) was a difficult patient to code
because of A-C drugs being used for bipolar illness and possible temporal lobe
symptomatology. It was agreed by JP and VN to treat him, like the other 2, as
indeterminate for the test of the hypothesis.<span style='mso-spacerun:yes'> 
</span><o:p></o:p></span></p>

<i style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=all style='page-break-before:always'>
</span></i>

<p class=MsoBodyTextIndent style='margin-top:12.0pt'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>SPE
Scores<o:p></o:p></span></i></p>

<p class=MsoBodyTextIndent style='text-indent:.5in'><span style='font-size:
12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Generation of the SPE scores
involved coding the frequency of the 4 INSET questions for SPEs, using
essentially the same coding as for the INSET questions for TLD:<span
style='mso-spacerun:yes'>  </span><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>0<span style='mso-spacerun:yes'> 
</span>=<span style='mso-spacerun:yes'>     </span>0 (never)<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>1<span style='mso-spacerun:yes'> 
</span>=<span style='mso-spacerun:yes'>     </span>1-2 (rare, yearly or
less,<span style='mso-spacerun:yes'>  </span>etc.)<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>2<span style='mso-spacerun:yes'> 
</span>=<span style='mso-spacerun:yes'>     </span>3 (occasional, more than
yearly up to monthly, etc.)<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:.5in'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;
color:windowtext'>3<span style='mso-spacerun:yes'>  </span>=<span
style='mso-spacerun:yes'>     </span>4-6 (frequent, more than monthly, etc.)<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:0in'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;
color:windowtext'>We decided to combine the two ESP questions because a few of
the sub-items overlapped and we wanted to avoid double scoring any
experiences.<span style='mso-spacerun:yes'>  </span>Each of the three remaining
items was scored only once, using the higher of the responses in either the
"recent" or "past" column. This gave a possible range of<span
style='mso-spacerun:yes'>   </span>0 - 9 for the raw SPE scores. <o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Per
pre-defined protocol, HN had reviewed the whole chart for SPEs. In three
instances, she had already recorded file notes of SPEs for ESP and presences,
described by patients after taking the INSET.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt'><span style='font-size:
12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'><span
style='mso-spacerun:yes'> </span><i style='mso-bidi-font-style:normal'>Phone
Interviews<o:p></o:p></i></span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;
margin-left:0in;text-indent:.5in;mso-layout-grid-align:none'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Because the information
about subjective ESP (S-ESP) experiences obtained from the INSET items was
sketchy, it was decided that JP would interview by phone as many patients as
possible who had reported </span><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;mso-fareast-font-family:"MS Mincho"'>S-ESP</span><span style='font-size:
12.0pt;mso-bidi-font-size:10.0pt'> experiences on INSET.<span
style='mso-spacerun:yes'>  </span>ESP experiences were singled out because they
are the most likely kind of SPE to have a true paranormal component. A second
objective of the interviews was to get patients' impressions of whether they noticed
any effect of the A-C medications they had been taking on the frequency of
their ESP experiences.<span style='mso-spacerun:yes'>  </span><o:p></o:p></span></p>

<p class=MsoBodyTextIndent2 style='margin-top:0in;mso-layout-grid-align:none'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>In order to protect his
patients, VN excluded from the interviews those with whom he could not discuss
the procedure face-to-face beforehand or whom he felt might be adversely
affected by the interview because of fragility. In one other case, the patient
declined to be interviewed.<span style='mso-spacerun:yes'>  </span>For these
reasons, only 20 of the 53 patients (37.7%) reporting S-ESP experiences were
designated for interview. However, VN considers them representative of the
larger sample in regard to S-ESP experiences.<span style='mso-spacerun:yes'> 
</span>Some of the interviews were conducted a considerable period of time
after the original obtaining of the source data, in some instances several
years. 18 of the 20 interviewees were female.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;
margin-left:0in;text-indent:.5in;mso-layout-grid-align:none'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe and Magill attempted
to reach these patients.<span style='mso-spacerun:yes'>  </span>If they
succeeded, the nature of the phone interview was described to them and informed
consent obtained.<span style='mso-spacerun:yes'>  </span>JP was given only the
first names of the patients.<span style='mso-spacerun:yes'>  </span>Because
these were not the same as the patient initials he had been given for the
purpose of coding clinical symptoms, he was effectively blind to how each
patient had been scored on these variables, at least during discussion of the
ESP experiences.<span style='mso-spacerun:yes'>  </span>The interviews were
tape recorded, with the patients' consent, and transcribed.<span
style='mso-spacerun:yes'>  </span>None of the patients expressed any
reservations about the taping.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;text-indent:.5in;mso-layout-grid-align:
none'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>During the
interviews, JP asked the patient to describe their most impressive ESP
experience, in the sense of which they would choose if they were trying to
convince a skeptical friend that ESP is real.<span style='mso-spacerun:yes'> 
</span>If the chosen experience did not appear to be genuine, JP asked for
another example.<span style='mso-spacerun:yes'>  </span>They were then asked to
indicate what specific anti-convulsant drugs they had taken during the course
of their treatment and whether they noticed an increase, decrease, or no change
in the frequency of their S-ESP experiences as a function of changes in their
drug regimen.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;text-indent:.5in;mso-layout-grid-align:
none'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Following the
interviews, JP rated on a 3-point scale the quality of the best ESP experience
described by the patient:<span style='mso-spacerun:yes'>  </span>(a) a "2"
meant that the experience was credible, in the sense that, if it occurred as
described, it was unlikely to be a mere coincidence and there was no prior
information available from which the event could be logically inferred. An
example of an experience in this category is one where the patient had an
impression of a traffic accident which he witnessed 7-minutes later and
included an accurate image of a child going through the car window; (b) a "1"
meant the experience was marginally credible.<span style='mso-spacerun:yes'> 
</span>An example here is a general statement that the patient often "knew"
that a particular person was about to phone them and that person in fact
promptly called; (c) a "0" meant that the experience was not credible, or the
patient denied having any ESP experiences.<span style='mso-spacerun:yes'> 
</span>An example here would be a general statement that the patient had
insights into what she had done wrong in her marriage. The effects of A-C drugs
on S-ESP were rated as positive (more SPEs with the change), negative, or none.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent3><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;text-decoration:none;text-underline:none'><o:p>&nbsp;</o:p></span></p>

<p class=MsoBodyTextIndent align=center style='margin-top:0in;text-align:center'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'><span
style='mso-spacerun:yes'> </span><span style='font-variant:small-caps !msorm;
text-transform:none !msorm'><span style='text-transform:uppercase'><span
style='mso-prop-change:"David Turissini" 20051221T1940'>Results</span></span></span><a
style='mso-footnote-id:ftn7' href="#_ftn7" name="_ftnref7" title=""><span
class=MsoFootnoteReference><span style='mso-special-character:footnote'><![if !supportFootnotes]><span
class=MsoFootnoteReference><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>[7]</span></span><![endif]></span></span></a><o:p></o:p></span></p>

<p class=MsoBodyTextIndent><i style='mso-bidi-font-style:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Scores</span></i><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='text-indent:.5in'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>SPEs</span></i><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>.<span
style='mso-spacerun:yes'>  </span>The mean SPE score was 2.54 (<i
style='mso-bidi-font-style:normal'>SD</i> =2.46).<span
style='mso-spacerun:yes'>  </span>The distribution shows a pronounced positive
skew.<span style='mso-spacerun:yes'>  </span>61% of the sample claimed at least
1 ESP experience, 29% claimed at least 1 OBE, and 35% claimed at least 1
encounter with a presence.<span style='mso-spacerun:yes'>  </span>The scores of
the 3 questions were moderately intercorrelated, with Spearman correlations
ranging from .345 to .536.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt;text-indent:.5in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;color:windowtext'>TLD Components</span></i><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>.<span style='mso-spacerun:yes'> 
</span>The 16-item INSET was shown to have a high Brown-Spearman odd-even
reliability of .863.<span style='mso-spacerun:yes'>  </span>The distribution of
classification scores for the 4 components of TLD are presented in Table 1, and
the relationships among them are presented in Table 2.<a style='mso-footnote-id:
ftn8' href="#_ftn8" name="_ftnref8" title=""><span class=MsoFootnoteReference><span
style='mso-special-character:footnote'><![if !supportFootnotes]><span
class=MsoFootnoteReference><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>[8]</span></span><![endif]></span></span></a>
Although these relationships are generally positive, only the one between EEG
and A-C response is substantial and significant.<span
style='mso-spacerun:yes'>  </span>The size of this effect is due to the fact
that patients not prescribed an A-C medication were coded 0 on A-C Response,
and the decision not to prescribe was heavily influenced by a normal EEG.<span
style='mso-spacerun:yes'>  </span>When these patients are excluded (see last
column of Table 2), the relationship vanishes.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>TLD
Hypothesis<o:p></o:p></span></i></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt;text-indent:.5in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;color:windowtext'>. </span></i><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;color:windowtext'>The 60 patients assigned to the TLD group had a mean
SPE score of 3.05 (<i style='mso-bidi-font-style:normal'>SD</i> =2.69).<span
style='mso-spacerun:yes'>  </span>The 27 patients in the control group had a
mean SPE score of 1.93 (<i style='mso-bidi-font-style:normal'>SD</i>
=1.90).<span style='mso-spacerun:yes'>  </span>The difference is marginally
significant by the non-parametric <i style='mso-bidi-font-style:normal'>U</i>
-Test (<i style='mso-bidi-font-style:normal'>U</i> =1021, <i style='mso-bidi-font-style:
normal'>p</i> = .049, one-tailed).<span style='mso-spacerun:yes'>  </span>Thus,
the TLD hypothesis is confirmed. (Recall that the remaining 13 patients were
classified as indeterminate.)<o:p></o:p></span></p>

<i style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=all style='page-break-before:always'>
</span></i>

<p class=MsoBodyTextIndent style='margin-top:12.0pt'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Gender<o:p></o:p></span></i></p>

<p class=MsoBodyTextIndent style='text-indent:.5in'><span style='font-size:
12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>JP noticed during his coding
of symptoms that the patients he was assigning to the TLD group tended to be
female and those he was assigning to the control group tended to be male.<span
style='mso-spacerun:yes'>  </span>This observation was confirmed in the formal
analyses, where it was found that 47 of the 60 females (78.3%) were assigned to
the TLD group and 14 of the 27 males (51.9%) were assigned to the control
group, &#967;<sup> 2</sup> (1, <i style='mso-bidi-font-style:normal'>N</i> =
87) = 7.93, <i style='mso-bidi-font-style:normal'>p</i> = .005.<span
style='mso-spacerun:yes'>  </span>JP also suspected that females would report
more SPEs than males, and this was confirmed by the data as well.<span
style='mso-spacerun:yes'>  </span>The 60 females had an SPE mean of 3.35,
compared to 1.26 for the 27 males (<i style='mso-bidi-font-style:normal'>U</i>
= 1054, <i style='mso-bidi-font-style:normal'>p</i> = .005).<span
style='mso-spacerun:yes'>  </span>This, of course, suggests that gender has a
strong potential to confound the TLD-SPE relationship.<span
style='mso-spacerun:yes'>  </span>To assess this, an analysis of covariance was
performed between TLD category and SPE, with gender as a covariate.<span
style='mso-spacerun:yes'>  </span>As expected, the TLD-SPE relationship became
nonsignificant, <i style='mso-bidi-font-style:normal'>F </i>(1,84) = 0.91, <i
style='mso-bidi-font-style:normal'>p</i> = .344.<span
style='mso-spacerun:yes'>  </span>Thus, with gender controlled for, the TLD
hypothesis is not confirmed.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Analysis
of Component Predictors</span></i><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;color:windowtext'><o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='text-indent:.5in'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'><span
style='mso-spacerun:yes'> </span></span></i><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'>To assess the independent
contributions of the components of TLD to the TLD-SPE relationship, these
components (INSET, Etiology, EEG, and A-C Response), plus gender, were treated
as predictors of SPEs in a multiple regression analysis.<a style='mso-footnote-id:
ftn9' href="#_ftn9" name="_ftnref9" title=""><span class=MsoFootnoteReference><span
style='mso-special-character:footnote'><![if !supportFootnotes]><span
class=MsoFootnoteReference><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>[9]</span></span><![endif]></span></span></a><span
style='mso-spacerun:yes'>  </span>The analysis was performed on all 100
cases.<span style='mso-spacerun:yes'>  </span>Only the independent
contributions of gender, <i style='mso-bidi-font-style:normal'>t</i>(94) = 2.98
, <i style='mso-bidi-font-style:normal'>p</i> = .004, and INSET, <i
style='mso-bidi-font-style:normal'>t</i>(94) = 4.74, <i style='mso-bidi-font-style:
normal'>p </i>&lt; .001, were significant.<span style='mso-spacerun:yes'>  
</span>The multiple <i style='mso-bidi-font-style:normal'>r</i> was .568.<span
style='mso-spacerun:yes'>  </span>The standardized regression coefficients, in
descending order, were as follows: INSET (.425), gender (.280), etiology
(.005), EEG (-.008), and A-C response<br>
(-.153).<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='text-indent:.5in'><span style='font-size:
12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'><span
style='mso-spacerun:yes'> </span>The INSET clearly has the strongest
relationship with SPEs among the four TLD components and it is significant
independent of gender.<span style='mso-spacerun:yes'>  </span>It means that the
positive TLD-SPE relationship is completely attributable to the INSET.<span
style='mso-spacerun:yes'>  </span>Gender continues to be an independently significant
predictor of SPEs. <o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:12.0pt'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Phone
Interviews<o:p></o:p></span></i></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;
margin-left:0in;text-indent:.5in;mso-layout-grid-align:none'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>S-ESP</span></i><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>.
Of the 20 patients interviewed, 13 (65%) received a credibility of score of 2,
5 (22.7%) received a score of 1, and 4 (18.2%) received a score of 0.<span
style='mso-spacerun:yes'>  </span>2 of the 4 patients who scored 0 contacted VN
privately to the effect that because they didn't know JP they did not share
with him their best experiences.<o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:.5in;mso-layout-grid-align:none'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>In addition, VN made his own
ratings based on his notes and recall about conversations with his patients
about their SPEs.<span style='mso-spacerun:yes'>  </span>His ratings reflected
SPEs in general more than JP's, who asked specifically about </span><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;mso-fareast-font-family:"MS Mincho"'>S-ESP</span><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'> experiences. His initial
ratings were somewhat more positive than JP's. He gave a rating of 2 to 16
patients (80%), a rating of 1 to 3 patients (15%), and for the remaining 1 he
felt he had too little information to make a rating (5%). On 2 cases where his
codings differed from JP's, he modified his original codings after consultation
with JP.<span style='mso-spacerun:yes'>  </span>This made his final ratings as
follows: 2: 14 patients (70%); 1: 5 patients (20%); no rating: 1 patients
(5%).<span style='mso-spacerun:yes'>  </span>The final ratings are illustrated
in Table 3.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:6.0pt;text-indent:.5in;mso-layout-grid-align:
none'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>JP interviewed 2
additional patients who, unbeknownst to him at the time, did not report any </span><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;mso-fareast-font-family:"MS Mincho"'>S-ESP
experiences on the INSET and thus were not among the 53 ESP-positive
patients.<span style='mso-spacerun:yes'>  </span>He gave both these patients a
rating of 1, and for 1 of these he had been tempted to make it 0. </span><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p></o:p></span></p>

<p class=MsoBodyTextIndent2 style='margin-top:12.0pt;mso-layout-grid-align:
none'><i style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt'>A-C Drugs</span></i><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt'>. Five patients had not taken A-C drugs and could
not give meaningful responses to the question, and 1 additional patient did not
comply with the request to take the prescribed A-C drugs.<span
style='mso-spacerun:yes'>  </span>Of the remaining 14, 8 (57.1%) claimed to JP
that at least one of the A-C drugs inhibited their ESP experiences, 2 (14.3%)
claimed at least one had a facilitating effect, and 4 (28.6%) claimed no effect
either way.<span style='mso-spacerun:yes'>  </span>There were no reliable indications
that any specific drug or drugs had a particular kind of effect or no
effect.<span style='mso-spacerun:yes'>  </span><o:p></o:p></span></p>

<p class=MsoBodyTextIndent2 style='mso-layout-grid-align:none'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>VN's initial codings
reflected the trend toward suppression of S-ESP experiences by drugs a bit more
strongly than JP's. He concluded that A-C drugs had an inhibiting effect on 13
of the 14 relevant patients (92.9%), and no effect on 1 patient (7.1%).
Following consultation with JP on the two cases in which JP coded for a
positive effect of the drug on S-ESP experiences, he modified one of his
ratings. Thus, the final tally for VN was: inhibiting effect, 12 of 14 (85.7%),
no effect, 2 of 14 (14.3%). The ratings are illustrated in Table 3.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent align=center style='margin-top:0in;text-align:center'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoBodyTextIndent align=center style='margin-top:0in;text-align:center'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'><span
style='mso-spacerun:yes'> </span><span style='font-variant:small-caps !msorm;
text-transform:none !msorm'><span style='text-transform:uppercase'><span
style='mso-prop-change:"David Turissini" 20051221T1940'>Discussion<o:p></o:p></span></span></span></span></p>

<p class=MsoBodyTextIndent style='text-indent:.5in'><span style='font-size:
12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>The most important finding
to emerge from the data analyses completed so far is the significant positive
relationship between SPE scores and scores on those INSET items scored for
TLD.<span style='mso-spacerun:yes'>  </span>This outcome confirms the earlier
results of Neppe (1983b), who found that members of the South African SPR who
reported SPEs scored higher on an earlier version of the INSET than those not
reporting SPEs.<span style='mso-spacerun:yes'>  </span>The only difference is
that in Neppe's (1983b) study, SPEs were treated as the independent variable
and in the present study the INSET TLD scores were the independent variable.
Thus, findings from a non-clinical population have been confirmed using a
clinical population, namely, that there is a correlation between temporal lobe
symptomatology and subjective paranormal experience. <o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='text-indent:.5in'><span style='font-size:
12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>The finding with INSET
supersedes and to an extent redefines the relationship between TLD and SPEs
that constituted the main hypothesis.<span style='mso-spacerun:yes'>  </span>It
is noteworthy in this connection that INSET scores did not correlate
significantly with any of the other contributors to the TLD
classification.<span style='mso-spacerun:yes'>  </span>This pattern of results
suggests that INSET is measuring something not reflected in patients' EEGs, for
example. <o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='text-indent:.5in'><span style='font-size:
12.0pt;mso-bidi-font-size:10.0pt;color:windowtext'>Gender revealed itself to be
confounding factor in the TLD-SPE relationship.<span style='mso-spacerun:yes'> 
</span>It could be that females have attributes that make them more susceptible
than males to seek out treatment for TLD related symptoms. In any event, our
findings seem to indicate that VN more frequently diagnoses his female patients
as having TLD than his male patients.<span style='mso-spacerun:yes'>   
</span>It is noteworthy that the gender difference applies to the EEG and
etiology codings, not just the INSET (see bottom of Table 4).<span
style='mso-spacerun:yes'>  </span>Thus, more is at play here than a possible
female bias to report more TLD symptoms or more frequent TLD symptoms than
males.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Even if these findings
reflect a genuine non-artefactual difference of temporal lobe symptoms in a
known group with temporal lobe dysfunction correlating with a higher incidence
of subjective paranormal experiences, the possibility still exists that the
findings reflect a personality predisposition or attitudinal or behavioral
response pattern in this population. This would imply that some people are more
likely to take note of experiences in their lives which they then interpret as
anomalous and that these same people may report experiential symptoms of
temporal lobe anomalies. However, this explanation is unlikely to explain the results
fully, as the specific cluster of symptoms that the patients had are very
uncommon in the general population. (Neppe, 1981a, c; Neppe and Tucker, 1992)
Moreover, the population of patients had diagnosed temporal lobe disease by a
recognized expert in the area (VN), and were being successfully medicated for
this. Nevertheless, the possibility exists that certain temporal lobe
dysfunction patients may be more predisposed to endorsing symptoms, and this
may explain why they may have endorsed more SPEs as well as temporal lobe
symptoms on the INSET. However, these patients had also separately had detailed
personality testing on Minnesota Multiphasic Personality Inventory and other
neuropsychological tests, as well as detailed clinical assessments and neuropsychiatric
evaluations over many sessions. These have not been analyzed as part of the
research, but it is VN's strong clinical impression that there was no
demonstrable personality type or attitudinal predisposition. Even if either of
these explanations exist, this does not rule out the clinically diagnosable
temporal lobe dysfunction.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent2 style='mso-layout-grid-align:none'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Overall, JP was reassured
about the general quality of the ESP experiences of the patients he interviewed
over the phone.<span style='mso-spacerun:yes'>  </span>He was surprised at how
articulate they were, and the great majority seemed to understand what was
necessary if an ESP experience is to be considered credible.<span
style='mso-spacerun:yes'>  </span>Recall that patients with serious psychiatric
problems were removed from the sample at the outset.<span
style='mso-spacerun:yes'>  </span>However, no claim is being made that any of
the experiences can be considered evidence for ESP.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent2 style='mso-layout-grid-align:none'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>It is clear from these data
that if an A-C drug has a perceived effect on S-ESP experiences, the effect is
most often to reduce their frequency.<span style='mso-spacerun:yes'>  </span>As
it was found from the original analyses that at least some of these drugs
almost universally helped alleviate patients' clinical symptoms, this
inhibitory effect on S-ESP suggests that to some degree S-ESP experiences and
the clinical symptoms have a common root.<o:p></o:p></span></p>

<p class=MsoBodyTextIndent2 style='margin-top:12.0pt;text-indent:0in;
mso-layout-grid-align:none'><i style='mso-bidi-font-style:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Limitations of the Study <o:p></o:p></span></i></p>

<p class=MsoNormal style='margin-top:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>There are limitations to the
current statistical analysis, all of which may have weakened the obtained
results:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>1) In addition to the Short
INSET being used here, VN interviewed the patients in significant detail about
their symptoms, meaning that the TLD side of symptom analysis was more detailed
than the short INSET itself. However, the same cannot be said about the SPE
analysis.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span
style='mso-spacerun:yes'> </span>2) In Neppe's (1983b) original work, extensive
and detailed information was obtained about subjects' SPEs, and this was used
to select an initial experimental group of &quot;subjective paranormal
experients&quot; that reflected an extreme level of ESP experiences.<span
style='mso-spacerun:yes'>  </span>This extreme group was compared to a control
group with no SPEs. We plan comparable exploratory analyses of the present
data, comparing patients reporting no SPEs versus those reporting large
numbers, based on our revised SPE scores. We will then look for specific
diagnostic factors that distinguish the two groups.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>3) Based on clinical
impression, VN feels many of the &quot;SPEs&quot; found in the control group
may not fit a more stringent definition of SPE. This is another reason for a
more detailed evaluation of these SPEs.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>4) A late methodological
decision was made to allocate a score of 2 for a handful of subjects in which
frequency of SPEs was not mentioned in the file. Although this was the proper
decision from a research methodology point of view, based on VN's clinical
experience a score of 1 may have been more appropriate for these patients.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>5) The EEG scores were based
on surface recordings that did not necessarily register possible deep-seated
pathological temporolimbic activity.<span style='mso-spacerun:yes'> 
</span>This may explain why some patients with high scores in the other TLD
diagnostic criteria revealed normal EEGs, thus producing a low correlation
between EEG and these other criteria and adversely affecting the predictability
of the SPE scores.<span style='mso-spacerun:yes'>  </span>Moreover, in the
original Neppe (1980b, 1983b) work on the SASPR population, despite the
subjects having numerous SPEs correlating with possible temporal lobe symptoms,
the EEGs were normal (Nelson and Neppe, 1980). <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>6) Responsiveness to
medication can be an excellent state-related index of the condition underlying
pharmacological toleration and responsiveness (Neppe, 1990), as well as tracing
underlying biochemical and electrical abnormality including ostensible SPEs and
geomagnetic variations (Neppe, 1999). The correlation between SPE frequency and
anticonvulsant responsiveness may be better measured by tracking the
differences in frequency of SPEs after administration of anticonvulsants, just
as the possible temporal lobe symptoms should also be so tracked. Our present
study instead used a generic score for anti-convulsant response. We plan to
follow up to obtain more longitudinal correlation data.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:6.0pt;text-indent:.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>7) In contrast with the
original Neppe (1980b, 1983b) SASPR study, this study did not distinguish state
and trait temporal lobe phenomena: The study looked at symptoms broadly
occurring over time, without directly correlating state related events. We hope
to clarify this difference in follow-up interviews with the subjects.<o:p></o:p></span></p>

<h5 style='margin-top:12.0pt;text-indent:0in'><span style='font-variant:small-caps !msorm;
text-transform:none !msorm'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";color:windowtext;text-transform:uppercase'><span
style='mso-prop-change:"David Turissini" 20051221T1940'>Conclusion<o:p></o:p></span></span></span></h5>

<h3 style='text-indent:.5in'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-weight:normal'>This is the first study demonstrating that subjects
with clinical temporal lobe dysfunction demonstrate a strong relationship
between their clinical temporal lobe symptomatology and SPEs.<span
style='mso-spacerun:yes'>  </span>Given the extremely detailed notes that were
reviewed and the care in accurate scoring, it appears to be a real,
non-artefactual statistical result. <o:p></o:p></span></h3>

<p class=MsoNormal style='margin-top:6.0pt;text-indent:.5in'><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoBodyTextIndent align=center style='margin-top:0in;margin-right:
0in;margin-bottom:6.0pt;margin-left:0in;text-align:center'><span
style='font-variant:small-caps !msorm;text-transform:none !msorm'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;color:windowtext;text-transform:
uppercase'><span style='mso-prop-change:"David Turissini" 20051221T1940'>References<o:p></o:p></span></span></span></p>

<p class=MsoNormal style='margin-right:-14.2pt'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.2in;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Hurst L. A. , &amp; Neppe,
V. M. (1981). A familial study of subjective paranormal experience in temporal
lobe dysfunction subjects. <i style='mso-bidi-font-style:normal'>Parapsychological
Journal of South Africa</i>. <b style='mso-bidi-font-weight:normal'>2</b>,
56-64.<o:p></o:p></span></p>

<p class=MsoHeading9 style='border:none;mso-padding-alt:0in 0in 0in 0in'><span
lang=EN-GB style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Makarec, K.,
&amp; Persinger, M. A. (1990).<span style='mso-spacerun:yes'> 
</span>Electroencephalographic validation of a <o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span
style='mso-spacerun:yes'>      </span>temporal lobe signs inventory in a normal
population.<span style='mso-spacerun:yes'>  </span><i style='mso-bidi-font-style:
normal'>Journal of Research in Personality, </i><b style='mso-bidi-font-weight:
normal'>24</b><i style='mso-bidi-font-style:normal'>, </i>323-327.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Nelson, G. K. (1970).<span
style='mso-spacerun:yes'>  </span>Preliminary study of electroencephalograms of
mediums. <i style='mso-bidi-font-style:normal'>Parapsychologia</i>, <b
style='mso-bidi-font-weight:normal'>4</b><i style='mso-bidi-font-style:normal'>,</i>
30-35.<o:p></o:p></span></p>

<p class=MsoBodyText style='margin-left:.25in;text-indent:-.25in;border:none;
mso-padding-alt:0in 0in 0in 0in'><span lang=EN-GB style='font-size:12.0pt;
mso-bidi-font-size:10.0pt'>Nelson G.K., &amp;<span style='mso-spacerun:yes'> 
</span>Neppe, V. M. (1980). The neurophysiological wave correlates of a
controlled sample of subjective paranormal experients: A preliminary report.<span
style='mso-spacerun:yes'>  </span><i style='mso-bidi-font-style:normal'>Parapsychological
Journal of South Africa </i>, <b style='mso-bidi-font-weight:normal'>1</b><i
style='mso-bidi-font-style:normal'>,</i> 99-101.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe, V. M. (1979). <i
style='mso-bidi-font-style:normal'><span style='mso-spacerun:yes'> </span>An
investigation of the relationship between temporal lobe symptomatology and
subjective paranormal experience.</i><span style='mso-spacerun:yes'> 
</span>MMed Psych thesis, University of the Witwatersrand.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe, V. M. (1980a).
Subjective paranormal experience. <i style='mso-bidi-font-style:normal'>Psi</i>
, <b style='mso-bidi-font-weight:normal'>2</b>(3), 2-3.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe, V. M. (1980b).
Subjective paranormal experience and temporal lobe symptomatology.<span
style='mso-spacerun:yes'>  </span><i style='mso-bidi-font-style:normal'>Parapsychological
Journal of South Africa</i>, <b style='mso-bidi-font-weight:normal'>1</b>,
78-98.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe, V. M.<span
style='mso-spacerun:yes'>  </span>(1981a). <i style='mso-bidi-font-style:normal'>A
study of déjà vu experience.</i><span style='mso-spacerun:yes'>  </span>PhD
Medical thesis, University of the Witwatersrand.<o:p></o:p></span></p>

<p class=MsoBodyText3 style='margin-left:.25in;text-indent:-.25in;border:none;
mso-padding-alt:0in 0in 0in 0in'><span lang=EN-GB style='font-size:12.0pt;
mso-bidi-font-size:10.0pt'>Neppe, V. M. (1981b). Symptomatology of temporal
lobe epilepsy.<span style='mso-spacerun:yes'>  </span><i style='mso-bidi-font-style:
normal'>South African Medical Journal</i>, <b style='mso-bidi-font-weight:normal'>60</b>,
902-907.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe, V. M. (1981c).
Non-epileptic symptoms of temporal lobe dysfunction.<span
style='mso-spacerun:yes'>  </span><i style='mso-bidi-font-style:normal'>South
African Medical Journal</i>, <b style='mso-bidi-font-weight:normal'>60</b>,
989-991. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe, V. M.<span
style='mso-spacerun:yes'>  </span>(1982).<span style='mso-spacerun:yes'> 
</span>Differing perspectives to the concept of temporal lobe epilepsy. <i
style='mso-bidi-font-style:normal'>The Leech, </i><b style='mso-bidi-font-weight:
normal'>52</b>, 6-10.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe, V. M. (1983a). <i
style='mso-bidi-font-style:normal'>The psychology of déjà vu: Have I been here
before?</i> Johannesburg: Witwatersrand University Press.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe, V. M. (1983b).<span
style='mso-spacerun:yes'>  </span>Temporal lobe symptomatology in subjective
paranormal experients. <i style='mso-bidi-font-style:normal'>Journal of the
American Society for Psychical Research</i>, <b style='mso-bidi-font-weight:
normal'>77</b>, 1-29.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe, V. M. (1983c): The
olfactory hallucination in the psychic [Abstract].<span
style='mso-spacerun:yes'>  </span>In W. G. Roll, J. Beloff, &amp; R. A. White
(Eds.) <i style='mso-bidi-font-style:normal'>Research in parapsychology 1982</i>
(pp. 234-237). Metuchen,<span style='mso-spacerun:yes'>  </span>NJ.: Scarecrow
Press.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe, V. M. (1983d).
Anomalies of smell in the subjective paranormal experient. <i style='mso-bidi-font-style:
normal'>Psychoenergetics</i>, <b style='mso-bidi-font-weight:normal'>5</b>,
11-27.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe,<span
style='mso-spacerun:yes'>  </span>V. M. (1990). <i style='mso-bidi-font-style:
normal'>Innovative psychopharmacotherapy</i> (Rev. Ed.). New York: Raven Press.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe,<span
style='mso-spacerun:yes'>  </span>V. M. (1999).<span style='mso-spacerun:yes'> 
</span><i style='mso-bidi-font-style:normal'>Cry the beloved mind: A
voyage<span style='mso-spacerun:yes'>  </span>of hope.</i> Seattle: Brainquest
Press / Brainvoyage.com<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe, V. M., &amp; Hurst L.
A. (1982). &quot;Psi-genetics&quot;: An organic perspective. <i
style='mso-bidi-font-style:normal'>Parapsychological Journal of South Africa </i><span
style='mso-spacerun:yes'> </span><b style='mso-bidi-font-weight:normal'>3</b>,
54-57.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe,<span
style='mso-spacerun:yes'>  </span>V. M., &amp; Tucker, G. J. (1988). Modern
perspectives on epilepsy in relation to psychiatry: Classification and
evaluation. <i style='mso-bidi-font-style:normal'>Hospital Community Psychiatry</i>,
<b style='mso-bidi-font-weight:normal'>39</b><i style='mso-bidi-font-style:
normal'>, </i>263-71.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Neppe,<span
style='mso-spacerun:yes'>  </span>V. M. , &amp; Tucker, G. J. (1992).<span
style='mso-spacerun:yes'>  </span>Neuropsychiatric aspects of seizure
disorders. In S. C. Yudofsky &amp; R. E. Hales (Eds.), <i style='mso-bidi-font-style:
normal'>Textbook of neuropsychiatry</i> (pp. 397-426). Washington, D.C.:
American Psychiatric Press.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Palmer, J. (1979).<span
style='mso-spacerun:yes'>  </span>A community mail survey of psychic
experiences.<span style='mso-spacerun:yes'>  </span><i style='mso-bidi-font-style:
normal'>Journal of the American Society for Psychical Research</i>, <b
style='mso-bidi-font-weight:normal'>73</b>, 221-251.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Palmer, J., &amp; Broughton,
R. S. (2000).<span style='mso-spacerun:yes'>  </span>An updated meta-analysis
of post-PRL ESP-Ganzfeld experiments: The role of standardness. <i
style='mso-bidi-font-style:normal'>Proceedings of presented papers: The
Parapsychological Association 43<sup>rd</sup> Annual Convention</i>, 224-240.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Persinger, M. A.
(1984).<span style='mso-spacerun:yes'>  </span>Propensity to report paranormal
experiences is correlated with temporal lobe signs.<span
style='mso-spacerun:yes'>  </span><i style='mso-bidi-font-style:normal'>Perceptual
and Motor Skills</i>, <b style='mso-bidi-font-weight:normal'>59</b>, 583-586.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Persinger, M. A.
(1989).<span style='mso-spacerun:yes'>  </span>Psi phenomena and temporal lobe
activity: The geomagnetic factor<span style='mso-spacerun:yes'> 
</span>[Abstract].<span style='mso-spacerun:yes'>  </span>In L. A. Henkel &amp;
R. E. Berger (Eds.), <i style='mso-bidi-font-style:normal'>Research in
parapsychology 1988 </i>(pp.121-156).<span style='mso-spacerun:yes'> 
</span>Metuchen, NJ: Scarecrow Press.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Persinger, M. A., &amp;
Makarec, K. (1993). Complex partial epileptic signs as a continuum from normals
to epileptics: Normative data and clinical populations.<span
style='mso-spacerun:yes'>  </span><i style='mso-bidi-font-style:normal'>Journal
of Clinical Psychology</i>, <b style='mso-bidi-font-weight:normal'>49</b>,
33-45.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Persinger, M. A., &amp;
Vaillant, P. M. (1985).<span style='mso-spacerun:yes'>  </span>Temporal lobe
signs and reports of subjective paranormal experiences in a normal population:
A replication. <i style='mso-bidi-font-style:normal'>Perceptual and Motor
Skills</i>, <b style='mso-bidi-font-weight:normal'>60</b>, 903-909.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Roll, W. G. (1966).<span
style='mso-spacerun:yes'>  </span>ESP and memory.<span
style='mso-spacerun:yes'>  </span><i style='mso-bidi-font-style:normal'>International
Journal of Neuropsychiatry</i>, <b style='mso-bidi-font-weight:normal'>2</b>,
505-521.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Roll, W. G. (1977).<span
style='mso-spacerun:yes'>  </span>Poltergeists.<span style='mso-spacerun:yes'> 
</span>In B. B. Wolman (Ed.), <i style='mso-bidi-font-style:normal'>Handbook of
parapsychology</i> (pp. 382-413).<span style='mso-spacerun:yes'>  </span>New
York: Van Nostrand Reinhold.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Sensky, T., Wilson, A.,
Petty, R., Fenwick, P. B. C., &amp; Rose, C. (1984).<span
style='mso-spacerun:yes'>  </span>The interictal personality traits of temporal
lobe epileptics: Religious belief and its association with reported mystical
experiences.<span style='mso-spacerun:yes'>  </span>In R. J. Porter et al.
(Eds.), <i style='mso-bidi-font-style:normal'>Advances in epileptology: XVth
Epilepsy International Symposium</i> (pp. 545-549).<span
style='mso-spacerun:yes'>  </span>New York: Raven Press.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Solfvin, G., &amp; Roll, W.
G. (1976).<span style='mso-spacerun:yes'>  </span>A case of RSPK with an
epileptic agent [Abstract]. In J. D. Morris, W. G. Roll, &amp; R. L. Morris
(Eds.), <i style='mso-bidi-font-style:normal'>Research in parapsychology 1975 </i>(pp.
115-120).<span style='mso-spacerun:yes'>  </span>Metuchen, NJ: Scarecrow Press.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>Rhine Research Center<o:p></o:p></span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>2741 Campus Walk Ave., Bldg. 500<o:p></o:p></span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>Durham, NC 27705, USA<o:p></o:p></span></i><a name="test"></a></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'><a href="mailto:john@rhine.org"><span style='color:windowtext;
text-decoration:none;text-underline:none'>john@rhine.org</span></a><o:p></o:p></span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'><o:p>&nbsp;</o:p></span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>Pacific Neuropsychiatric Institute<o:p></o:p></span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>10330 Meridian Ave. N, Suite 380<o:p></o:p></span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>Seattle, WA 98133, USA<o:p></o:p></span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>psyche@pni.org<br style='mso-special-character:line-break'>
<![if !supportLineBreakNewLine]><br style='mso-special-character:line-break'>
<![endif]></span></i><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<b style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-variant:small-caps !msorm;text-transform:none !msorm'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;text-transform:uppercase'><span
style='mso-prop-change:"David Turissini" 20051221T1940'>Appendix <o:p></o:p></span></span></span></p>

<div style='mso-element:para-border-div;border:none;border-bottom:solid windowtext 1.0pt;
mso-border-bottom-alt:solid windowtext .75pt;padding:0in 0in 1.0pt 0in'>

<p class=MsoNormal align=center style='text-align:center;border:none;
mso-border-bottom-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:0in 0in 1.0pt 0in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Specific TLD and SPE Items
from INSET<o:p></o:p></span></p>

</div>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><i style='mso-bidi-font-style:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>TLD</span></i><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>:<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>1)
How often do you have ( ) fits, ( ) seizures or ( ) &quot;peculiar spells"?<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>2)
How often have you had a ( ) blackout or ( ) lost consciousness for a short
period <u>for no reason</u>?<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>3)
How often have you had ( ) grand mal or ( ) petit mal or ( ) myoclonic or <br>
( ) psychomotor seizures?<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>4)
How often do you have or are you told that you at times <u>lose</u> contact
with ( ) staring spells or ( ) absences or ( ) episodes where you have a blank
look on your face ( ) for seconds or ( ) minutes <u>no</u>t hours?<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>6)
How often have you for a very short time like seconds or minutes been <u>completely
unaware</u> that you did or been told that you did any of the following:<span
style='mso-spacerun:yes'>  </span>( ) odd behaviors like ( ) buttoning /
unbuttoning; ( ) chewing / mouth movements or ( ) other unusual movements or (
) doing very strange things or ( ) saying strange things or ( ) finding
yourself in places you don't remember going to or ( ) jerking the arms?<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>7)
How often do you ( ) have clear cut gaps<span style='mso-spacerun:yes'> 
</span>in your memory during which you totally cannot remember anything for 5
minutes or more; ( ) miss major sections of TV shows you have been watching; (
) find yourself driving without remembering how you got there or where you are
going; ( ) do strange things automatically? Include <u>only</u> if you think
these are <u>not only because of difficulty you have concentrating</u>.<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>8)
How often do your (<span style='mso-spacerun:yes'>  </span>) moods, ( )
feelings or ( ) thoughts fluctuate <u>within minutes</u> for no reason [like
moods which are one moment ( ) very happy then very sad]?<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>11)
How often do you have <u>odd sensations</u> in part of your body like (<span
style='mso-spacerun:yes'>  </span>) floating,<br>
( ) turning or ( ) moving when you were doing none of those? <o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>12)
How often have you come across a <u>smell</u> when there is nothing to cause
it? If so, what kind (check applicable)?<span style='mso-spacerun:yes'> 
</span>( ) medicine;<span style='mso-spacerun:yes'>  </span>( ) steak;<span
style='mso-spacerun:yes'>  </span>( ) perfume;<span style='mso-spacerun:yes'> 
</span>( ) flowers;<br>
( ) burning;<span style='mso-spacerun:yes'>  </span>( ) rotting;<span
style='mso-spacerun:yes'>  </span>( ) synthetic;<span
style='mso-spacerun:yes'>  </span>( ) vomit;<span style='mso-spacerun:yes'> 
</span>( ) incense;<span style='mso-spacerun:yes'>  </span>( ) musty;<span
style='mso-spacerun:yes'>  </span>( ) grass;<span class=msoIns><ins
cite="mailto:Rhine%20Research%20Center" datetime="2002-09-27T17:00"><br>
</ins></span><span class=msoDel><del cite="mailto:Rhine%20Research%20Center"
datetime="2002-09-27T17:00"><span style='mso-spacerun:yes'>  </span></del></span>(
) bitter;<span style='mso-spacerun:yes'>   </span>( ) sweet;<span
style='mso-spacerun:yes'>  </span>( ) cake; ( ) mustard;<span
style='mso-spacerun:yes'>  </span>( ) other __________ [ONLY "BURNING",
"ROTTING" SCORED]<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>13)
How often have you <u>seen</u> any of the following when there is no-one or
nothing to cause it?<span style='mso-spacerun:yes'>   </span>( ) dots;<span
style='mso-spacerun:yes'>  </span>( ) lights;<span style='mso-spacerun:yes'> 
</span>( ) patterns;<span style='mso-spacerun:yes'>  </span>( ) shapes;<span
style='mso-spacerun:yes'>  </span>( ) wrong size;<span
style='mso-spacerun:yes'>  </span>( ) movements;<span
style='mso-spacerun:yes'>  </span><br>
( ) distortions;<span style='mso-spacerun:yes'>  </span>( ) things moving; (( )
stars;<span style='mso-spacerun:yes'>   </span>( ) bugs;<span
style='mso-spacerun:yes'>  </span>( ) threads;<span style='mso-spacerun:yes'> 
</span>( ) insects;<span style='mso-spacerun:yes'>  </span>( ) none;<br>
( ) other ___________________ [ONLY "MOVEMENTS", "DISTORTIONS", "WRONG SIZE"
SCORED]<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>15)
How often do you <u>hear</u> any of the following, when there is no-one or
nothing to cause it?<span style='mso-spacerun:yes'>  </span>( )<span
style='mso-spacerun:yes'>  </span>buzz;<span style='mso-spacerun:yes'> 
</span>( ) ring;<span style='mso-spacerun:yes'>  </span>( ) sizz;<span
style='mso-spacerun:yes'>  </span>( ) hiss;<span style='mso-spacerun:yes'> 
</span>( ) tap;<span style='mso-spacerun:yes'>  </span>( ) songs;<span
style='mso-spacerun:yes'>  </span>( ) whistling;<span
style='mso-spacerun:yes'>  </span>( ) music;<br>
( ) single word;<span style='mso-spacerun:yes'>  </span>( ) arguing;<span
style='mso-spacerun:yes'>  </span>( )<span style='mso-spacerun:yes'> 
</span>names;<span style='mso-spacerun:yes'>  </span>( )<span
style='mso-spacerun:yes'>  </span>voices;<span style='mso-spacerun:yes'> 
</span>( )<span style='mso-spacerun:yes'>  </span>jumble;<span
style='mso-spacerun:yes'>  </span>( )<span style='mso-spacerun:yes'> 
</span>message;<br>
( )<span style='mso-spacerun:yes'>  </span>instructing;<span
style='mso-spacerun:yes'>  </span>( )<span style='mso-spacerun:yes'> 
</span>radio / TV;<span style='mso-spacerun:yes'>  </span>( ) phone; ( )
nothing; () other<span style='mso-spacerun:yes'>  </span>__________ [ONLY
"BUZZ", "RING", "HISS", "TAP" SCORED] <o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>19)
How often have you been in a familiar place and had the impression that you
have <u>never</u> been in that place before? (the opposite of déjà vu called
jamais vu - not recognized at all, totally unfamiliar)<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>23)
How often have you found that, for no apparent reason, you are actually
reliving things in the past (as if the past flows like a <u>movie screen</u>
before you)?<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>28)
How often do you have sudden, unexplained and uncontrollable attacks of intense
fear?<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>34)
How often do you <u>hear</u> what is being said, yet you cannot understand or
make sense of it?<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>48)
How often do you have frightening nightmares?<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>-----------------------------------------------------------------------------------------------------------<o:p></o:p></span></p>

<p class=MsoNormal><i style='mso-bidi-font-style:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>SPE</span></i><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>:<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>49)
How often have you had ( ) premonitions or ( ) &quot;psychic&quot;, ( )
intuitive or<br>
( ) paranormal experiences such as (<span style='mso-spacerun:yes'>  </span>)
knowing the future , ( ) sensing correctly unknown past knowledge , (<span
style='mso-spacerun:yes'>  </span>) having dreams which came true,<span
style='mso-spacerun:yes'>  </span>or (<span style='mso-spacerun:yes'>  </span>)
strange feelings which came <u>true</u>?<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>50)<span
style='mso-spacerun:yes'>  </span>How often have you felt you've ( ) seen
events that happened at a great distance before or while they were happening or
( ) been in touch with someone when they were far away from you or dead?<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>51)
How often have you felt you have (<span style='mso-spacerun:yes'>  </span>)
left your body or (<span style='mso-spacerun:yes'>  </span>) had an out of body
experience?<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>52)
How often have you been aware of a presence of someone whom you could not see?<o:p></o:p></span></p>

<p class=MsoBodyTextIndent style='margin-top:0in'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Table 1<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Frequencies of Diagnostic
Codes<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;tab-stops:right 2.0in 3.0in 4.0in 5.0in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span style='mso-tab-count:
1'>                                  </span>0<span style='mso-tab-count:1'>                      </span>1<span
style='mso-tab-count:1'>                      </span>2<span style='mso-tab-count:
1'>                      </span>3<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;tab-stops:right 2.0in 3.0in 4.0in 5.0in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>---------------------------------------------------------------------------------<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;tab-stops:right 2.0in 3.0in 4.0in 5.0in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>INSET<span style='mso-tab-count:
1'>                       </span>9<span style='mso-tab-count:1'>                    </span>32<span
style='mso-tab-count:1'>                    </span>18<span style='mso-tab-count:
1'>                    </span>41<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;tab-stops:right 2.0in 3.0in 4.0in 5.0in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>ETIOLOGY<span
style='mso-tab-count:1'>             </span>47<span style='mso-tab-count:1'>                    </span>44<span
style='mso-tab-count:1'>                      </span>9<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;tab-stops:right 2.0in 3.0in 4.0in 5.0in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>EEG<span style='mso-tab-count:
1'>                         </span>28<span style='mso-tab-count:1'>                    </span>14<span
style='mso-tab-count:1'>                    </span>24<span style='mso-tab-count:
1'>                    </span>34<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;tab-stops:right 2.0in 2.05in 3.0in 4.0in 5.0in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>A-C RESPONSE<span
style='mso-tab-count:1'>   </span> 23<span style='mso-tab-count:1'> </span><sup>a</sup><span
style='mso-tab-count:1'>                   </span>16<sup><span
style='mso-tab-count:1'>                           </span></sup>36<span
style='mso-tab-count:1'>                    </span>25<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;tab-stops:right 2.0in 3.0in 4.0in 5.0in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>---------------------------------------------------------------------------------<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;tab-stops:right 2.0in 3.0in 4.0in 5.0in'><sup><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>a</span></sup><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'> Includes 1 score of<span
style='mso-spacerun:yes'>  </span>-1.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;tab-stops:right 2.0in 3.0in 4.0in 5.0in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Table 2<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Relationships Among
Predictors Expressed as <o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Spearman Correlation
Coefficients<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;tab-stops:1.5in 2.25in 3.0in 3.75in 4.5in 5.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span style='mso-tab-count:
1'>                        </span>INSET<span style='mso-tab-count:1'>       </span>ETIO.<span
style='mso-tab-count:1'>        </span>EEG<span style='mso-tab-count:1'>           </span>A-C
RSP.<span style='mso-tab-count:1'>  </span>A-C RSP (2)<sup>a</sup><span
style='mso-tab-count:1'>   </span><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;tab-stops:right 2.0in 3.0in 4.0in 5.0in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>------------------------------------------------------------------------------------------<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;tab-stops:decimal 1.5in 2.25in 3.0in 3.75in 4.5in 5.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>INSET<span style='mso-tab-count:
2'>                               </span>.080<span style='mso-tab-count:1'>           </span>.120<span
style='mso-tab-count:1'>           </span>.110<span style='mso-tab-count:1'>          </span>-.083<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;tab-stops:decimal 1.5in 2.25in 3.0in 3.75in 4.5in 5.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>ETIOLOGY<span
style='mso-tab-count:3'>                                         </span>.081<span
style='mso-tab-count:1'>          </span>-.011<span style='mso-tab-count:1'>          </span>-.057<o:p></o:p></span></p>

<h1 style='margin-left:.5in;tab-stops:decimal 1.5in 2.25in 3.0in 3.75in 4.5in 5.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-style:normal'>EEG<span
style='mso-tab-count:4'>                                                                       </span>.361
***<span style='mso-tab-count:1'>    </span>.000<span style='mso-tab-count:
2'>                 </span><span style='mso-spacerun:yes'>             </span><o:p></o:p></span></h1>

<p class=MsoNormal style='margin-left:.5in'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt'>-------------------------------------------------------------------------------------------<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;tab-stops:decimal 1.5in 2.25in 3.0in 3.75in 4.5in 5.25in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>SEX<span style='mso-tab-count:
1'>                 </span>.285**<span style='mso-tab-count:1'>      </span>-.198<span
style='mso-tab-count:1'>           </span>.252*<span style='mso-tab-count:1'>         </span>.148<span
style='mso-tab-count:1'>          </span>-.050<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt'>-------------------------------------------------------------------------------------------<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in'><sup><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt'>a</span></sup><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt'>Only patients who were prescribed an A-C medication,
<i style='mso-bidi-font-style:normal'>N </i>= 80.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt'>*** <i style='mso-bidi-font-style:normal'>p</i> &lt;
.001;<span style='mso-spacerun:yes'>  </span>** <i style='mso-bidi-font-style:
normal'>p</i> &lt; .01;<span style='mso-spacerun:yes'>  </span>* <i
style='mso-bidi-font-style:normal'>p</i> &lt; .05<o:p></o:p></span></p>

<p class=MsoNormal align=center style='margin-top:12.0pt;margin-right:0in;
margin-bottom:6.0pt;margin-left:0in;text-align:center;mso-layout-grid-align:
none'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Table 3<br>
Final Ratings on Phone Interview Questions<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;mso-layout-grid-align:none'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span style='mso-tab-count:
1'>            </span><span style='mso-spacerun:yes'>            
</span>---------------------------------------------------------------------<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;tab-stops:1.3in 3.3in;mso-layout-grid-align:
none'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span
style='mso-tab-count:1'>                               </span>QUALITY OF S-ESP<span
style='mso-tab-count:1'>             </span>EFFECT OF DRUGS<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;tab-stops:center 1.5in 2.0in 2.5in 3.5in 4.0in 4.5in;
mso-layout-grid-align:none'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'><span style='mso-tab-count:2'>                                              </span>JP<span
style='mso-tab-count:1'>       </span>VN<span style='mso-tab-count:2'>                               </span>JP<span
style='mso-tab-count:1'>       </span>VN<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;tab-stops:center 1.5in 2.0in 2.5in 3.5in 4.0in 4.5in;
mso-layout-grid-align:none'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'><span style='mso-tab-count:1'>                                </span><u>Score<span
style='mso-tab-count:1'>      </span><i style='mso-bidi-font-style:normal'>N</i><span
style='mso-tab-count:1'>         </span><i style='mso-bidi-font-style:normal'>N</i><span
style='mso-tab-count:1'>                  </span>Effect<span style='mso-tab-count:
1'>      </span><i style='mso-bidi-font-style:normal'>N</i><span
style='mso-tab-count:1'>         </span><i style='mso-bidi-font-style:normal'>N</i><span
style='mso-spacerun:yes'>                    </span><o:p></o:p></u></span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;tab-stops:center 1.5in 2.0in 2.5in 3.5in 4.0in 4.5in;
mso-layout-grid-align:none'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'><span style='mso-tab-count:1'>                                   </span>2<span
style='mso-tab-count:1'>         </span>13<span style='mso-tab-count:1'>        </span>14<span
style='mso-tab-count:1'>                  </span>Neg.<span style='mso-tab-count:
1'>       </span>8<span style='mso-tab-count:1'>         </span>12<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;tab-stops:center 1.5in 2.0in 2.5in 3.5in 4.0in 4.5in;
mso-layout-grid-align:none'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'><span style='mso-tab-count:1'>                                   </span>1<span
style='mso-tab-count:1'>          </span>4<span style='mso-tab-count:1'>          </span>5<span
style='mso-tab-count:1'>                   </span>None<span style='mso-tab-count:
1'>       </span>4<span style='mso-tab-count:1'>          </span>2<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;tab-stops:center 1.5in 2.0in 2.5in 3.5in 4.0in 4.5in;
mso-layout-grid-align:none'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'><span style='mso-tab-count:1'>                                   </span>0<span
style='mso-tab-count:1'>         </span> 3<sup>a</sup><span style='mso-tab-count:
1'>         </span>0<span style='mso-tab-count:1'>                    </span>Pos.<span
style='mso-tab-count:1'>        </span>2<span style='mso-tab-count:1'>          </span>0<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;tab-stops:center 1.5in 2.0in 2.5in 3.5in 4.0in 4.5in;
mso-layout-grid-align:none'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'><span style='mso-tab-count:1'>                                </span><span
style='mso-spacerun:yes'> </span>N/R<sup>b</sup><span style='mso-tab-count:
1'>       </span>0<span style='mso-tab-count:1'>          </span>1<span
style='mso-tab-count:1'>                   </span> N/R<sup>b</sup><span
style='mso-tab-count:1'>       </span>0<span style='mso-tab-count:1'>          </span>0<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;tab-stops:center 1.5in 2.0in 2.5in 3.5in 4.0in 4.5in;
mso-layout-grid-align:none'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'><span style='mso-tab-count:1'>                                </span>Total<span
style='mso-tab-count:1'>      </span>20<span style='mso-tab-count:1'>        </span>20<span
style='mso-tab-count:1'>                  </span>Total<span style='mso-tab-count:
1'>      </span>14<span style='mso-tab-count:1'>        </span>14<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;text-indent:.5in;mso-layout-grid-align:
none'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span
style='mso-spacerun:yes'>       
</span>--------------------------------------------------------------------------<br>
<span style='mso-spacerun:yes'>  </span><span style='mso-tab-count:1'>          </span><span
style='mso-spacerun:yes'>       </span><sup>a</sup>Includes 2 patients who told
VN they under-reported<br>
<span style='mso-spacerun:yes'> </span><span style='mso-tab-count:1'>           </span><span
style='mso-spacerun:yes'>             </span>S-ESP experiences to JP<br>
<span style='mso-tab-count:1'>            </span><span
style='mso-spacerun:yes'>       </span><sup>b</sup>N/R means not rated.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

</div>

<div style='mso-element:footnote-list'><![if !supportFootnotes]><br clear=all>

<hr align=left size=1 width="33%">

<![endif]>

<div style='mso-element:footnote' id=ftn1>

<p class=MsoFootnoteText><a style='mso-footnote-id:ftn1' href="#_ftnref1"
name="_ftn1" title=""><span class=MsoFootnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'>[1]</span></span><![endif]></span></span></a> We are
grateful to the Bial Foundation for supporting this research,and to Heidi Nebel
and Stacie Magill for their assistance in its conduct.</p>

</div>

<div style='mso-element:footnote' id=ftn2>

<p class=MsoNormal><a style='mso-footnote-id:ftn2' href="#_ftnref2" name="_ftn2"
title=""><span class=MsoFootnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'>[2]</span></span><![endif]></span></span></a> All
names were changed to initials and numbers (first in the series, 1 and if a
duplicate initial, 2 , </p>

<p class=MsoFootnoteText>then 3, etc.).</p>

</div>

<div style='mso-element:footnote' id=ftn3>

<p class=MsoNormal><a style='mso-footnote-id:ftn3' href="#_ftnref3" name="_ftn3"
title=""><span class=MsoFootnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'>[3]</span></span><![endif]></span></span></a> To
create profiles for SPE ranking (for HN), all INSET questions not pertaining to
SPE,<span style='mso-spacerun:yes'>  </span>déjà </p>

<p class=MsoNormal>vu, or presences, plus any<span style='mso-spacerun:yes'> 
</span>temporal lobe terminology, seizure terminology, and diagnosis
information, were extracted.<span style='mso-spacerun:yes'>  </span>For the
ranking of temporal lobe symptomatology (for JP all information about SPEs,
ESP, PK, intuition, presences, déjà vu, OBEs, and auras was extracted, leaving
all temporal lobe and diagnostic information.</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

</div>

<div style='mso-element:footnote' id=ftn4>

<p class=MsoFootnoteText><a style='mso-footnote-id:ftn4' href="#_ftnref4"
name="_ftn4" title=""><span class=MsoFootnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'>[4]</span></span><![endif]></span></span></a> At the
time of the editing, both HN and SM were employees of the Pacific
Neuropsychiatric Institute.<span style='mso-spacerun:yes'>  </span>SM took over
the duties from HN when SM was added to the staff. JP was appointed an honorary
staff member prior to the start of the study.</p>

</div>

<div style='mso-element:footnote' id=ftn5>

<p class=MsoFootnoteText><a style='mso-footnote-id:ftn5' href="#_ftnref5"
name="_ftn5" title=""><span class=MsoFootnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'>[5]</span></span><![endif]></span></span></a> JP
attempted his own codings of these cases before mailing them to VN.<span
style='mso-spacerun:yes'>  </span>His codings matched VN's in 10 of the 16
cases.<span style='mso-spacerun:yes'>  </span>In 5 of these misses, JP was 1
number too low; in the 6<sup>th</sup>, he was 1 number too high. The final TLD
classifications of these 6 patients would not be changed had JP's codings been
used.</p>

</div>

<div style='mso-element:footnote' id=ftn6>

<p class=MsoFootnoteText><a style='mso-footnote-id:ftn6' href="#_ftnref6"
name="_ftn6" title=""><span class=MsoFootnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'>[6]</span></span><![endif]></span></span></a><span
style='mso-spacerun:yes'>  </span>VN spontaneously recalled more than 90 of the
patients in detail. Those that he did not were generally patients who had not
consulted him for a year or more and whose case histories had not required review
during that time.</p>

</div>

<div style='mso-element:footnote' id=ftn7>

<p class=MsoFootnoteText><a style='mso-footnote-id:ftn7' href="#_ftnref7"
name="_ftn7" title=""><span class=MsoFootnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'>[7]</span></span><![endif]></span></span></a> All <i
style='mso-bidi-font-style:normal'>p</i> values are two-tailed unless noted
otherwise.</p>

</div>

<div style='mso-element:footnote' id=ftn8>

<p class=MsoFootnoteText><a style='mso-footnote-id:ftn8' href="#_ftnref8"
name="_ftn8" title=""><span class=MsoFootnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'>[8]</span></span><![endif]></span></span></a> Prior to
analysis, subgroups of less than 10 were combined with an adjacent group.</p>

</div>

<div style='mso-element:footnote' id=ftn9>

<p class=MsoFootnoteText><a style='mso-footnote-id:ftn9' href="#_ftnref9"
name="_ftn9" title=""><span class=MsoFootnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'>[9]</span></span><![endif]></span></span></a> The
regression analysis was performed on a Spearman correlation matrix.</p>

</div>

</div>





			    </td>
              </tr>
            </table>
<!--ARTICLE LINKS MENU-->
<p>
<SCRIPT LANGUAGE="JavaScript" SRC="http://www.pni.org/links.js"></SCRIPT>
</p>
<!--END ARTICLE LINKS MENU-->            
          </td>
        </tr>
        <tr>
          <td height="29"><img src="../../bottom.jpg" width="700" height="29" border="0" usemap="#Map3"></td>
        </tr>
      </table></td>
  </tr>
</table>
<p align="center"><br>
  <font size="2" face="Arial, Helvetica, sans-serif">Copyright &copy;1997-2018 
  Pacific Neuropsychiatric Institute</font><br>
</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<map name="Map3">
  <area shape="rect" coords="237,3,385,23" href="http://pni.org/about_pni.html">
  <area shape="rect" coords="410,5,566,25" href="http://www.pni.org/disclaimer.html">
  <area shape="rect" coords="582,3,682,26" href="http://www.pni.org/credits.html">
</map>
</body>
<!-- InstanceEnd --></html>
